FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Vechi, HT
   de Sousa, ASV
   da Cunha, MA
   Shaw, JJ
   Luz, KG
AF Vechi, Hareton Teixeira
   Vasconcelos de Sousa, Ana Solange
   da Cunha, Mirella Alves
   Shaw, Jeffrey Jon
   Luz, Kleber Giovanni
TI Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl
   Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated
   Visceral Leishmaniasis in a Splenectomized Adult Patient
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID INFANTUM; SUSCEPTIBILITY
AB In immunocompromised patients, visceral leishmaniasis (VL) can present with atypical clinical symptoms that include poor response to treatment. No optimal therapeutic regimen is available for such cases. In a splenectomized male patient, we observed a disseminated form of the disease in the liver, bone marrow, lymph nodes, and gastrointestinal tract. There was an apparent clinical improvement when he was initially treated with liposomal amphotericin B(L-AmB), but this was followed by a relapse involving severe clinical symptoms. He was finally treated successfully with a combination of L-AmB, meglumine antimoniate, and pentamidine isethionate. It is important to include asplenia as an immunosuppressive condition that induces exotic VL pathologies. In such cases, combination anti-Leishmania drug therapy should be considered.
C1 [Vechi, Hareton Teixeira; da Cunha, Mirella Alves; Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Hosp Giselda Trigueiro, Dept Infect Dis, 110 Conego Monte St, BR-59037170 Natal, RN, Brazil.
   [Vasconcelos de Sousa, Ana Solange] Hosp Giselda Trigueiro, Natal, RN, Brazil.
   [Shaw, Jeffrey Jon] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, SP, Brazil.
RP Luz, KG (corresponding author), Univ Fed Rio Grande do Norte, Hosp Giselda Trigueiro, Dept Infect Dis, 110 Conego Monte St, BR-59037170 Natal, RN, Brazil.
EM haretonvechi@gmail.com; anasolv@gmail.com; mirellaac@gmail.com;
   jayusp@hotmail.com; klebergluz@gmail.com
OI Vechi, Hareton/0000-0001-7845-3921
CR Adamama-Moraitou KK, 2007, AM J TROP MED HYG, V76, P53, DOI 10.4269/ajtmh.2007.76.53
   Agarwal P, 2017, CYTOJOURNAL, V14, DOI 10.4103/1742-6413.205312
   Aleixo JA, 2006, T ROY SOC TROP MED H, V100, P79, DOI 10.1016/j.trstmh.2005.06.025
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   [Anonymous], 2010, WHO TECHN REP SER, V2010, p[xiii, 1]
   Aronson N, 2016, CLIN INFECT DIS, V63, pE202, DOI 10.1093/cid/ciw670
   Belo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982
   CARTWRIGHT GE, 1948, BLOOD, V3, P249, DOI 10.1182/blood.V3.3.249.249
   Chapman LAC, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1136-3
   Chattopadhyay A, 2011, BIOCHEM BIOPH RES CO, V416, P7, DOI 10.1016/j.bbrc.2011.11.023
   Cota GF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002195
   Croft SL, 2018, PARASITOLOGY, V145, P237, DOI 10.1017/S0031182017001664
   Croft SL, 2002, CURR PHARM DESIGN, V8, P319, DOI 10.2174/1381612023396258
   Dutra RA, 2012, REV SOC BRAS MED TRO, V45, P130, DOI 10.1590/S0037-86822012000100027
   Eibl M, 1985, Prog Pediatr Surg, V18, P139
   Gomes MAF, 2018, REV SOC BRAS MED TRO, V51, P393, DOI 10.1590/0037-8682-0398-2017
   GONZALEZ JL, 1986, BRIT J EXP PATHOL, V67, P353
   IDOATE MA, 1993, HISTOPATHOLOGY, V22, P589, DOI 10.1111/j.1365-2559.1993.tb00182.x
   Kumar R, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-17
   Lachaud L, 2009, CLIN INFECT DIS, V48, pE16, DOI 10.1086/595710
   Lindoso JA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003136
   de Assis TSM, 2017, REV SOC BRAS MED TRO, V50, P478, DOI 10.1590/0037-8682-0133-2017
   Magill AJ, 2015, MANDELL DOUGLAS BENN, P3097
   Maia C, 2013, EXP PARASITOL, V135, P36, DOI 10.1016/j.exppara.2013.05.015
   MCBRIDE JA, 1968, BRIT J HAEMATOL, V14, P225, DOI 10.1111/j.1365-2141.1968.tb01489.x
   Ministerio da Saude do Brasil, 2006, MAN VIG CONTR LEISHM, P31
   Ministerio da Saude do Brasil, 2011, LEISHM VISC REC CLIN, P17
   Morizot G, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004304
   NAPIER L E, 1949, J Trop Med Hyg, V52, P243
   Olea P, 2013, REV CHIL INFECTOL, V30, P216, DOI 10.4067/S0716-10182013000200013
   Osakwe Nwamaka M, 2013, Mil Med, V178, pe386, DOI 10.7205/MILMED-D-12-00407
   Pomares-Estran C, 2009, ANN TROP MED PARASIT, V103, P555, DOI 10.1179/000349809X12459740922093
   Saporito L, 2013, INT J INFECT DIS, V 17, pE572, DOI 10.1016/j.ijid.2012.12.024
   SIDDIG M, 1990, TROP GEOGR MED, V42, P107
   van Griensven J, 2014, CLIN MICROBIOL INFEC, V20, P286, DOI 10.1111/1469-0691.12556
   Varma N, 2010, INDIAN J HEMATOL BLO, V26, P78, DOI 10.1007/s12288-010-0027-1
   Woods ML, 2018, KUCERS USE ANTIBIOTI, P3324
NR 37
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD FEB
PY 2020
VL 102
IS 2
BP 268
EP 273
DI 10.4269/ajtmh.18-0999
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KK6WZ
UT WOS:000512881500008
PM 31872796
DA 2020-12-15
ER

PT J
AU de Brito, CAA
   Marques, CDL
   Falcao, MB
   da Cunha, RV
   Simon, F
   Valadares, LDD
   Luz, KG
   Melo, CFCDE
   Albuquerque, DD
   de Brito, MCM
   Duarte, ALBP
AF Antunes de Brito, Carlos Alexandre
   Lopes Marques, Claudia Diniz
   Falcao, Melissa Barreto
   da Cunha, Rivaldo Venancio
   Simon, Fabrice
   de Azevedo Valadares, Lilian David
   Luz, Kleber Giovanni
   de Albuquerque e Melo, Carlos Frederico Campelo
   Albuquerque Filho, Dalcy de Oliveira
   Moraes de Brito, Marina Coelho
   Branco Pinto Duarte, Angela Luzia
TI Update on the treatment of musculoskeletal manifestations in chikungunya
   fever: a guideline
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Review
DE Chikungunya fever; Musculoskeletal pain; Arbovirus; Management
ID MANAGEMENT; INFECTION; ARTHRITIS; VIRUS
AB Since the emergence of the chikungunya virus in Brazil in 2014, more than 700,000 cases have been reported throughout the country, corresponding to one-third of all cases reported in the Americas. In addition to its high attack rates, resulting in hundreds of thousands of cases, the disease has high chronicity rates with persistent joint manifestations for more than 3 months, which can spread to more than half of the patients affected in the acute phase. Pain associated with musculoskeletal manifestations, often disabling, has an effect on patients' quality of life at different stages of the disease. Currently, the challenge faced by specialists is identifying the best therapy to be instituted for symptom relief despite the limited number of published intervention studies. In 2016, a multidisciplinary group published pharmacological treatment protocols for pain in patients with chikungunya, which was incorporated into the guidelines for clinical management of the Brazilian Ministry of Health in 2017; in that same year, a consensus was published by the Brazilian Society of Rheumatology about diagnosis and treatment. After 5 years of experience with chikungunya epidemics, in 2019, specialists involved in the protocols of the Brazilian Society of Rheumatology and Brazilian Ministry of Health prepared an update with the main objective of developing flowcharts for the therapeutic approach of musculoskeletal manifestations in adult patients to enable specialists at different levels of healthcare to spread and apply this guideline in a systematic and simplified manner.
C1 [Antunes de Brito, Carlos Alexandre; Lopes Marques, Claudia Diniz; Branco Pinto Duarte, Angela Luzia] Univ Fed Pernambuco, Dept Med Clin, Recife, PE, Brazil.
   [Falcao, Melissa Barreto] Univ Estadual Feira de Santana, Nucleo Pesquisa & Extensao Vigilancia Saude, Feira De Santana, BA, Brazil.
   [da Cunha, Rivaldo Venancio] Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil.
   [Simon, Fabrice] Aix Marseille Univ, Unite Virus Emergents, IRD 190, Inserm 1207,IHU Mediterranee Infect, F-13015 Marseille, France.
   [de Azevedo Valadares, Lilian David] Hosp Getulio Vargas Pernambuco, Recife, PE, Brazil.
   [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Inst Med Trop, Natal, RN, Brazil.
   [de Albuquerque e Melo, Carlos Frederico Campelo] Unidade Tecn Doencas Transmissiveis & Analise Sit, Org Pan Amer Saude, Brasilia, DF, Brazil.
   [Albuquerque Filho, Dalcy de Oliveira] Minist Saude, Secretaria Vigilancia Saude, Brasilia, DF, Brazil.
   [Moraes de Brito, Marina Coelho] Univ Fed Pernambuco, Ctr Ciencias Med, Recife, PE, Brazil.
   [Lopes Marques, Claudia Diniz; Branco Pinto Duarte, Angela Luzia] Univ Fed Pernambuco, Hosp Clin, Serv Reumatol, Recife, PE, Brazil.
RP de Brito, CAA (corresponding author), Univ Fed Pernambuco, Dept Med Clin, Recife, PE, Brazil.
EM cbritoc@gmail.com
OI Coelho Moraes de Brito, Marina/0000-0002-9298-3184
CR Amaral JK, 2018, ARTHRIT CARE RES, V70, P1501, DOI 10.1002/acr.23519
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P668, DOI 10.1590/0037-8682-0279-2016
   Blettery M, 2016, ARTHRITIS RHEUMATOL, V68, P2817, DOI 10.1002/art.39775
   Bouquillard E, 2009, JOINT BONE SPINE, V76, P654, DOI 10.1016/j.jbspin.2009.08.005
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2019, B EPIDEMIOL, P1
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2017, B EP, V48, P1
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Secretaria de Atencao Basica, 2017, SECR AT BAS
   BRIGHTON SW, 1984, S AFR MED J, V66, P217
   Cunha RV, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005319
   de Andrade DC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-31
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   Ganu Mohini A, 2011, J Assoc Physicians India, V59, P83
   Gerardin P, 2018, EMERG INFECT DIS, V24, P1773, DOI 10.3201/eid2409.180724
   Greenhalgh T, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12931
   Javelle E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003603
   Marques CDL, 2017, REV BRAS REUMATOL, V57, P421, DOI DOI 10.1016/J.RBR.2017.05.004
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Padmakumar B, 2009, INDIAN J RHEUMATOL, V4, P94, DOI DOI 10.1016/S0973-3698(10)60189-6
   Paixao ES, 2018, T ROY SOC TROP MED H, V112, P301, DOI 10.1093/trstmh/try063
   Pan American Health Organization, 2013, NEW CAS CHIK AM, P8
   Pandya S., 2008, INDIAN J RHEUMATOL, V3, P93, DOI DOI 10.1016/S0973-3698(10)60125-2
   Ramachandran V, 2012, PLOS ONE, V7
   Ravindran V, 2017, CLIN RHEUMATOL, V36, P1335, DOI 10.1007/s10067-016-3429-0
   Renault P, 2007, AM J TROP MED HYG, V77, P727
   Rodriguez-Morales AJ, 2016, ARTHRIT CARE RES, V68, P1849, DOI 10.1002/acr.22900
   Rother ET, 2007, ACTA PAUL        JUN, V20, pv
   Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137
   Simon F, 2015, MED MALADIES INFECT, V45, P243, DOI 10.1016/j.medmal.2015.05.007
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
NR 29
TC 0
Z9 0
U1 1
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2020
VL 53
AR e20190517
DI 10.1590/0037-8682-0517-2019
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA MZ0PU
UT WOS:000558826500001
PM 32756797
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Biswal, S
   Reynales, H
   Saez-Llorens, X
   Lopez, P
   Borja-Tabora, C
   Kosalaraksa, P
   Sirivichayakul, C
   Watanaveeradej, V
   Rivera, L
   Espinoza, F
   Fernando, L
   Dietze, R
   Luz, K
   da Cunha, RV
   Jimeno, J
   Lopez-Medina, E
   Borkowski, A
   Brose, M
   Rauscher, M
   LeFevre, I
   Bizjajeva, S
   Bravo, L
   Wallace, D
AF Biswal, Shibadas
   Reynales, Humberto
   Saez-Llorens, Xavier
   Lopez, Pio
   Borja-Tabora, Charissa
   Kosalaraksa, Pope
   Sirivichayakul, Chukiat
   Watanaveeradej, Veerachai
   Rivera, Luis
   Espinoza, Felix
   Fernando, LakKumar
   Dietze, Reynaldo
   Luz, Kleber
   da Cunha, Rivaldo Venancio
   Jimeno, Jose
   Lopez-Medina, Eduardo
   Borkowski, Astrid
   Brose, Manja
   Rauscher, Martina
   LeFevre, Inge
   Bizjajeva, Svetlana
   Bravo, Lulu
   Wallace, Derek
CA TIDES Study Grp
TI Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and
   Adolescents
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SAFETY; IMMUNOGENICITY
AB BACKGROUND
   Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.
   METHODS
   We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin America in which the disease is endemic. Healthy children and adolescents 4 to 16 years of age were randomly assigned in a 2:1 ratio (stratified according to age category and region) to receive two doses of vaccine or placebo 3 months apart. Participants presenting with febrile illness were tested for virologically confirmed dengue by serotype-specific reverse-transcriptase polymerase chain reaction. The primary end point was overall vaccine efficacy in preventing virologically confirmed dengue caused by any dengue virus serotype.
   RESULTS
   Of the 20,071 participants who were given at least one dose of vaccine or placebo (safety population), 19,021 (94.8%) received both injections and were included in the per-protocol analysis. The overall vaccine efficacy in the safety population was 80.9% (95% confidence interval [CI], 75.2 to 85.3; 78 cases per 13,380 [0.5 per 100 person-years] in the vaccine group vs. 199 cases per 6687 [2.5 per 100 person-years] in the placebo group). In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cases of virologically confirmed dengue in the vaccine group vs. 149 cases in the placebo group), with 95.4% efficacy against dengue leading to hospitalization (95% CI, 88.4 to 98.2; 5 hospitalizations in the vaccine group vs. 53 hospitalizations in the placebo group). Planned exploratory analyses involving the 27.7% of the per-protocol population that was seronegative at baseline showed vaccine efficacy of 74.9% (95% CI, 57.0 to 85.4; 20 cases of virologically confirmed dengue in the vaccine group vs. 39 cases in the placebo group). Efficacy trends varied according to serotype. The incidence of serious adverse events was similar in the vaccine group and placebo group (3.1% and 3.8%, respectively).
   CONCLUSIONS
   TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic.
C1 [Biswal, Shibadas] Takeda Vaccines, 21 Biopolis Rd,Level 4, Singapore 138567, Singapore.
   [Reynales, Humberto] Ctr Atenc & Invest Med, Bogota, Colombia.
   [Lopez, Pio; Lopez-Medina, Eduardo] Univ Valle, Ctr Estudios Infectol Pediat, Ctr Med Imbanaco, Cali, Colombia.
   [Lopez, Pio; Lopez-Medina, Eduardo] Univ Valle, Dept Pediat, Cali, Colombia.
   [Saez-Llorens, Xavier; Jimeno, Jose] Hosp Nino Dr Jose Renan Esquivel, Secretaria Nacl Ciencia & Tecnol SENACYT, Ctr Vacunac Int Cevaxin, Sistema Nacl Invest,Dept Infect Dis, Panama City, Panama.
   [Borja-Tabora, Charissa] Res Inst Trop Med, Muntinlupa, Philippines.
   [Bravo, Lulu] Univ Philippines Manila, Ermita, Philippines.
   [Kosalaraksa, Pope] Khon Kaen Univ, Srinagarind Hosp, Khon Kaen, Thailand.
   [Sirivichayakul, Chukiat] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, Bangkok, Thailand.
   [Watanaveeradej, Veerachai] Phramongkutklao Hosp, Bangkok, Thailand.
   [Rivera, Luis] Hosp Maternidad Nuestra Senora Altagracia, Santo Domingo, Dominican Rep.
   [Espinoza, Felix] Natl Autonomous Univ Nicaragua, Leon, Spain.
   [Fernando, LakKumar] Negombo Gen Hosp, Ctr Clin Management Dengue & Dengue Haemorrhag Fe, Negombo, Sri Lanka.
   [Dietze, Reynaldo] Univ Fed Espirito Santo, Hosp Univ Cassiano Antonio de Moraes, Vitoria, ES, Brazil.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, Inst Med Trop, Natal, RN, Brazil.
   [da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Campo Grande, MS, Brazil.
   [Borkowski, Astrid; Brose, Manja; Rauscher, Martina; LeFevre, Inge; Bizjajeva, Svetlana] Takeda Pharmaceut Int, Zurich, Switzerland.
   [Wallace, Derek] Takeda Vaccines, Boston, MA USA.
RP Biswal, S (corresponding author), Takeda Vaccines, 21 Biopolis Rd,Level 4, Singapore 138567, Singapore.
EM shibadas.biswal@takeda.com
RI Moreira, Edson D/J-1758-2012
OI Moreira, Edson D/0000-0002-7081-8348; Dietze,
   Reynaldo/0000-0002-6995-8001
FU Takeda Vaccines
FX Supported by Takeda Vaccines.
CR [Anonymous], 2018, WKLY EPIDEMIOL REC, V36, P457
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Huang CYH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002243
   Huang CYH, 2003, J VIROL, V77, P11436, DOI 10.1128/JVI.77.21.11436-11447.2003
   Osorio JE, 2011, VACCINE, V29, P7251, DOI 10.1016/j.vaccine.2011.07.020
   Saez-Llorens X, 2018, LANCET INFECT DIS, V18, P162, DOI 10.1016/S1473-3099(17)30632-1
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Villar LA, 2013, PEDIATR INFECT DIS J, V32, P1102, DOI 10.1097/INF.0b013e31829b8022
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   World Health Organization, 2019, IMM VACC BIOL DENG
   World Health Organization, 2019, DENG SEV DENG
   World Health Organization, DENGUE CONTROL
   World Health Organization, 2017, DENG VACC RES
   Yoksan S, 1986, ARBOVIRUS RES AUSTR, P35
NR 18
TC 45
Z9 45
U1 5
U2 11
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 21
PY 2019
VL 381
IS 21
BP 2009
EP 2019
DI 10.1056/NEJMoa1903869
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA JZ6NB
UT WOS:000505218800005
PM 31693803
OA Bronze
DA 2020-12-15
ER

PT J
AU Zambrano, B
   Rivera, DM
   Arredondo, JL
   Reynales, H
   Luz, K
   Deseda, C
   Bonaparte, M
   Langevin, E
   Wu, YK
   Cortes, M
   Dayan, GH
   Granados, CD
   Savarino, S
   Noriega, F
AF Zambrano, Betzana
   Maribel Rivera, Doris
   Luis Arredondo, Jose
   Reynales, Humberto
   Luz, Kleber
   Deseda, Carmen
   Bonaparte, Matthew
   Langevin, Edith
   Wu, Yukun
   Cortes, Margarita
   Dayan, Gustavo H.
   Granados, Carlos Diaz
   Savarino, Stephen
   Noriega, Fernando
TI PRIOR VACCINATION WITH CYD-TDV DID NOT POTENTIATE SYMPTOMATIC ZIKA IN
   DENGUE ENDEMIC AREAS OF LATIN AMERICA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 20-24, 2019
CL National Harbor, MD
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Bavarian Nord, GSK, Takeda, Integrum Sci, Celgene, Vulcan, Plos Neglected Trop Dis, Elsevier
C1 [Zambrano, Betzana] Sanofi Pasteur, Montevideo, Uruguay.
   [Maribel Rivera, Doris] Invers Invest Med, Tegucigalpa, Honduras.
   [Luis Arredondo, Jose] Inst Nacl Pediat, Mexico City, DF, Mexico.
   [Reynales, Humberto] Ctr Atenc & Invest Med, Bogota, Colombia.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, Natal, RN, Brazil.
   [Deseda, Carmen] Caribbean Travel Med Clin, San Juan, PR USA.
   [Bonaparte, Matthew; Wu, Yukun; Dayan, Gustavo H.; Granados, Carlos Diaz; Savarino, Stephen; Noriega, Fernando] Sanofi Pasteur, Swiftwater, PA USA.
   [Langevin, Edith] Sanofi Pasteur, Marcy Letoile, France.
   [Cortes, Margarita] Sanofi Pasteur, Bogota, Colombia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2019
VL 101
SU 5
MA 1367
BP 420
EP 420
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KC7PF
UT WOS:000507364504077
DA 2020-12-15
ER

PT J
AU Wanderley, NRS
   Gomes, MAF
   de Medeiros, LLC
   Lobo, FPD
   Lima, CBF
   Monteiro, MGL
   Luz, KG
AF Silva Wanderley, Nathalia Rayane
   Ferreira Gomes, Maria Antonia
   Cantidio de Medeiros, Lana Lira
   Dantas Lobo, Fernanda Paula
   Fernandes Lima, Carlos Bruno
   Lins Monteiro, Maria Goretti
   Luz, Kleber Giovanni
TI Childhood Sarcoidosis mimicking Tuberculosis: A case report
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Childhood sarcoidosis; Mimicking; Tuberculosis
AB Sarcoidosis is a rare multisystem chronic inflammatory disease in children We present a case of a five-year-old child with clinical features mimicking several diseases, including tuberculosis. After failure of treatment based on the suspected diagnosis, an axillary lymph node biopsy showed noncaseating granulomas compatible with samoidosis and appropriate treatment was then started.
C1 [Silva Wanderley, Nathalia Rayane; Lins Monteiro, Maria Goretti] Hosp Infantil Varela Santiago, Natal, RN, Brazil.
   [Ferreira Gomes, Maria Antonia; Cantidio de Medeiros, Lana Lira; Dantas Lobo, Fernanda Paula; Fernandes Lima, Carlos Bruno] Univ Potiguar, Escola Saude, Natal, RN, Brazil.
   [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Inst Med Trop Rio Grande Norte, Dept Doencas Infecciosas, Natal, RN, Brazil.
RP Wanderley, NRS (corresponding author), Hosp Infantil Varela Santiago, Natal, RN, Brazil.
EM nathaliaray.wanderley@gmail.com
OI Wanderley, Nathalia/0000-0003-0364-2706
CR Brasil (MS), 2014, TECNICAS APLICACAO L
   Cemlyn-Jones J, 2009, REV PORT PNEUMOL, V15, P543
   Angarita TD, 2016, ARCH ARGENT PEDIATR, V114, pE323, DOI 10.5546/aap.2016.e323
   El Sayed F, 2013, DERMATOLOGY ONLINE J, V19
   Fauroux Brigitte, 2005, Paediatr Respir Rev, V6, P128, DOI 10.1016/j.prrv.2005.03.007
   Fortuna FP, 2000, J PNEUMOL, V26, P259
   Gokdemir Y, 2013, ARCH ARGENT PEDIATR, V111, pE113, DOI [10.5546/aap.2013.e113, 10.1590/S0325-00752013000500014]
   Nunes H, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-46
   Rossoni AM, 2013, PULMAO RJ, V22, P65
   Sant'Anna C C, 1998, J Pediatr (Rio J), V74 Suppl 1, pS69
   Zombini EV, 2013, J HUMAN GROWTH DEV, V23, P52
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2019
VL 52
AR UNSP e20180229
DI 10.1590/0037-8682-0229-2018
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA IL1MU
UT WOS:000477065000001
PM 31340353
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Luz, KG
AF Luz, K. G.
TI Zika congenital syndorme: experience in Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Luz, K. G.] Hosp Giselda Trigueiro, Natal, RN, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2018
VL 73
SU S
MA 48.002
BP 70
EP 70
DI 10.1016/j.ijid.2018.04.3586
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA GO8MP
UT WOS:000440345100152
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Gomes, MAF
   de Medeiros, LLC
   Lobo, FPD
   Wanderley, NRS
   Matos, APR
   Jacome, TD
   Monteiro, MGL
   Luz, KG
AF Ferreira Gomes, Maria Antonia
   Cantidio de Medeiros, Lana Lira
   Dantas Lobo, Fernanda Paula
   Silva Wanderley, Nathalia Rayane
   Rodrigues Matos, Ana Paula
   Jacome, Tacito do Nascimento
   Lins Monteiro, Maria Goretti
   Luz, Kleber Giovanni
TI Combination therapy with liposomal amphotericin b (ambisome),
   n-methylglucamine antimoniate (glucantime), and pentamidine isethionate
   in a refractory visceral leishmaniasis case
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Visceral leishmaniasis; Refractory; Treatment
AB Visceral leishmaniasis is a systemic disease that is potentially severe and endemic in Brazil. It clinically manifests as fever, weight loss, swelling, hepatosplenomegaly, paleness, and edema. In this study, we discuss a case of a 1-year-old child diagnosed with refractory visceral leishmaniasis after being treated with liposomal amphotericin B in two distinct occasions. Considering the persistent clinical features and weak response to conventional treatment, a combination therapy with liposomal amphotericin B (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate was initiated, and response to treatment was good.
C1 [Ferreira Gomes, Maria Antonia; Cantidio de Medeiros, Lana Lira; Dantas Lobo, Fernanda Paula] Univ Potiguar, Escola Saude, Natal, RN, Brazil.
   [Silva Wanderley, Nathalia Rayane; Rodrigues Matos, Ana Paula] Hosp Infantil Varela Santiago, Natal, RN, Brazil.
   [Jacome, Tacito do Nascimento] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Natal, RN, Brazil.
   [Lins Monteiro, Maria Goretti] Hosp Infantil Varela Santiago, Dept Residencia Med, Natal, RN, Brazil.
   [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Inst Med Trop Rio Grande Norte, Dept Doencas Infecciosas, Natal, RN, Brazil.
RP Gomes, MAF (corresponding author), Univ Potiguar, Escola Saude, Natal, RN, Brazil.
EM fgomesmaria@hotmail.com
OI Wanderley, Nathalia/0000-0003-0364-2706
CR ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2
   Barbosa IR, 2013, SCI MED, V23, P5
   Caldas AJM, 2014, REV PESQ SAUDE, V14, P91
   de Alvarenga DG, 2010, REV SOC BRAS MED TRO, V43, P194, DOI 10.1590/S0037-86822010000200017
   Dionisio MT, 2011, ACTA MEDICA PORT, V24, P399
   Dutra RA, 2012, REV SOC BRAS MED TRO, V45, P130, DOI 10.1590/S0037-86822012000100027
   Fundacao Oswaldo Cruz (FIOCRUZ), 1997, LEISHM TRAT
   Ministerio da Saude (MS), 2009, SECR VIG SAUD GUIA V
   MS - Ministerio da Saude, 2016, GUIA VIG SAUD
   Roatt BM, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00272
   Scandar SAS, 2011, OCORRENCIA LEISHMANI, V8, P13
   Werneck Guilherme L., 2010, Cad. Saúde Pública, V26, P644, DOI 10.1590/S0102-311X2010000400001
NR 12
TC 3
Z9 3
U1 1
U2 2
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD APR-JUN
PY 2018
VL 51
IS 3
BP 393
EP 396
DI 10.1590/0037-8682-0398-2017
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA GL3IM
UT WOS:000437026000025
PM 29972577
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Dourado, ME
   Fernandes, U
   Vital, AL
   Ramos, E
   Urbano, JC
   Sena, A
   Fraiman, PHA
   Luz, K
   Queiroz, JW
   Jeronimo, SMB
AF Dourado, M. E.
   Fernandes, U.
   Vital, A. L.
   Ramos, E.
   Urbano, J. C.
   Sena, A.
   Fraiman, P. H. A.
   Luz, K.
   Queiroz, J. W.
   Jeronimo, S. M. B.
TI HIGH INCIDENCE OF GUILLAIN-BARRE SYNDROME AFTER ZIKA VIRUS INFECTION IN
   THE STATE RIO GRANDE DO NORTE, IN NORTHEAST BRAZIL
SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
LA English
DT Meeting Abstract
CT Peripheral-Nerve-Society Meeting
CY JUL 08-12, 2017
CL Sitges, SPAIN
SP Peripheral Nerve Soc, Alnylam Pharmaceut Inc, CSL Behring, Grifols S A, Kedr S p A, Pfizer Inc Rare Dis, Terumo BCT Inc, Shire Plc, GBS CIDP Fdn Int, Octapharma AG, Acceleron Pharma Inc, Ionis Pharmaceut Inc, LFB Biomedicaments, Mayo Med Labs, Pharnext SA, Hereditary Neuropathy Fdn, Syntimmune Inc, UCB Biosciences Inc
C1 [Dourado, M. E.; Fernandes, U.; Vital, A. L.; Ramos, E.; Urbano, J. C.; Sena, A.; Fraiman, P. H. A.; Luz, K.; Queiroz, J. W.; Jeronimo, S. M. B.] Univ Fed Rio Grande do Norte, Natal, RN, Brazil.
RI Jeronimo, Selma/AAY-4033-2020
OI Jeronimo, Selma/0000-0002-4784-9904
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1085-9489
EI 1529-8027
J9 J PERIPHER NERV SYST
JI J. Peripher. Nerv. Syst.
PD SEP
PY 2017
VL 22
IS 3
BP 275
EP 276
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA FF8CU
UT WOS:000409243500125
DA 2020-12-15
ER

PT J
AU Neto, NNM
   Maia, JTD
   Zacarkim, MR
   Rolim, DD
   Linz, MG
   Trindade, TG
   Luz, K
   Fulco, G
   Mendes, TV
   Vidal, SJA
   Muniz, IAC
   de Souza, SMP
   Queiroz, I
   LaBeaud, AD
AF Mendes Neto, Nilson Nogueira
   da Silva Maia, Jessika Thais
   Zacarkim, Marcelo Rodrigues
   Rolim, Daniel Duarte
   Linz, Maria Goretti
   Trindade, Thiago Gomes
   Luz, Kleber
   Fulco, Giovanna
   Mendes, Tatyana Vidal
   Alves Vidal, Sebastiana Jayne
   Cortez Muniz, Iracema Augusta
   Pinheiro de Souza, Servulo Marciano
   Queiroz, Igor
   LaBeaud, Angelle Desiree
TI MORTALITY IN NEWBORNS WITH MICROCEPHALY DUE TO MATERNAL ZIKA VIRUS
   INFECTION IN RIO GRANDE DO NORTE STATE - NORTHEAST BRAZIL: A
   CROSSSECTIONAL STUDY
SO NEUROLOGY
LA English
DT Meeting Abstract
C1 [Mendes Neto, Nilson Nogueira] UCDavis, Giselda Trigueiro Hosp, Natal, RN, Brazil.
   [da Silva Maia, Jessika Thais] Univ Potiguar, Boston, MA USA.
   [Zacarkim, Marcelo Rodrigues] Harvard Med Sch, Campina Grande, Paraiba, Brazil.
   [Rolim, Daniel Duarte] FCM, Natal, RN, Brazil.
   [Linz, Maria Goretti] Varela Santiago Hosp Infantil, Natal, RN, Brazil.
   [Trindade, Thiago Gomes; Luz, Kleber; Cortez Muniz, Iracema Augusta] Univ Fed Rio Grande do Norte, Natal, RN, Brazil.
   [Fulco, Giovanna; Queiroz, Igor] UnP, Cajazeiras, PB, Brazil.
   [Mendes, Tatyana Vidal] FSM, Natal, RN, Brazil.
   [Alves Vidal, Sebastiana Jayne] SESAP, Natal, RN, Brazil.
   [Pinheiro de Souza, Servulo Marciano] Brazilian Navy, Natal, RN, Brazil.
   [LaBeaud, Angelle Desiree] Stanford Childrens Hlth, Stanford, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD APR 18
PY 2017
VL 88
SU 16
MA S40.003
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA VJ3HU
UT WOS:000577381505323
DA 2020-12-15
ER

PT J
AU de Brito, CAA
   von Sohsten, AKA
   Leitao, CCD
   de Brito, RDCM
   Valadares, LDD
   da Fonte, CAM
   de Mesquita, ZB
   Cunha, RV
   Luz, K
   Leao, HMC
   de Brito, CM
   Frutuoso, LCV
AF Antunes de Brito, Carlos Alexandre
   Arraes von Sohsten, Ana Karla
   de Sa Leitao, Clezio Cordeiro
   Coelho Moraes de Brito, Rita de Cssia
   de Azevedo Valadares, Lilian David
   Magnata da Fonte, Caroline Araujo
   de Mesquita, Zelina Barbosa
   Cunha, Rivaldo Venancio
   Luz, Kleber
   Carneiro Leao, Helena Maria
   de Brito, Cecilia Moraes
   Vinhal Frutuoso, Livia Carla
TI Pharmacologic management of pain in patients with Chikungunya: a
   guideline
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Review
DE Chikungunya; Pain; Arthralgia; Arbovirus; Treatment
ID VIRUS-INFECTION; PERSISTENT ARTHRALGIA; REUNION ISLAND; ARTHRITIS;
   MANIFESTATIONS; CHLOROQUINE; SEVERITY; THERAPY; COHORT
AB From the arrival of Chikungunya virus in the Americas in 2013 until March 2016, approximately two million cases of the disease have been reported. In Brazil, the virus was identified in 2014 and thousands of people have been affected. The disease has high attack rates, infecting 50% of a population within a few months. Approximately 50% of infected people develop chronic symptoms lasting for months or years. Joint involvement is the main clinical manifestation of Chikungunya. It is characterized by swelling and intense pain that is poorly responsive to analgesics, both in the acute and chronic phase of the disease. This significantly compromises quality of life and may have immeasurable psychosocial and economic repercussions, constituting therefore, a serious public health problem requiring a targeted approach. Physicians are often not familiar with how to approach the management of pain, frequently prescribing limited analgesics, such as dipyrone, in sub-therapeutic doses. In addition, there are few published studies or guidelines on the approach to the treatment of pain in patients with Chikungunya. Some groups of specialists from different fields have thus developed a protocol for the pharmacologic treatment of Chikungunya-associated acute and chronic joint pain; this will be presented in this review.
C1 [Antunes de Brito, Carlos Alexandre; de Sa Leitao, Clezio Cordeiro] Univ Fed Pernambuco, Dept Med Clin, Recife, PE, Brazil.
   [Arraes von Sohsten, Ana Karla] Real Hosp Portugues Beneficencia Pernambuco, Inst Tratamento Dor, Recife, PE, Brazil.
   [Coelho Moraes de Brito, Rita de Cssia] Univ Pernambuco, Dept Pediat, Recife, PE, Brazil.
   [de Azevedo Valadares, Lilian David] Hosp Agamenom Magalhaes, Dept Reumatol, Recife, PE, Brazil.
   [Magnata da Fonte, Caroline Araujo] Hosp Getulio Vargas, Dept Reumatol, Recife, PE, Brazil.
   [de Mesquita, Zelina Barbosa] Inst Med Integral Prof Fernando Figueira, Dept Pediat, Recife, PE, Brazil.
   [Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Dept Infectol, Campo Grande, MS, Brazil.
   [Cunha, Rivaldo Venancio] Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, Dept Infectol, Natal, RN, Brazil.
   [Carneiro Leao, Helena Maria] Conselho Reg Med Pernambuco, Escola SUper Eet & Bioet, Recife, PE, Brazil.
   [de Brito, Cecilia Moraes] Univ Pernambuco, Curso Grad Med, Recife, PE, Brazil.
   [Vinhal Frutuoso, Livia Carla] Minist Saude, Programa Nacl Controle Dengue, Brasilia, DF, Brazil.
RP de Brito, CAA (corresponding author), Univ Fed Pernambuco, Dept Med Clin, Recife, PE, Brazil.
EM cbritoc@gmail.com
RI Frutuoso, Livia Vinhal/AAP-2745-2020
OI Frutuoso, Livia Vinhal/0000-0001-7926-1075
CR Alla SAO, 2011, BEST PRACT RES CL RH, V25, P337, DOI 10.1016/j.berh.2011.03.005
   Arroyo-Avila M, 2015, P R HEALTH SCI J, V34, P71
   Assuncao-Miranda I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/973516
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Borgherini G, 2008, CLIN INFECT DIS, V47, P469, DOI 10.1086/590003
   Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010
   Caglioti C, 2013, NEW MICROBIOL, V36, P211
   Chopra A, 2014, ARTHRITIS RHEUMATOL, V66, P319, DOI 10.1002/art.38221
   Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042
   de Andrade DC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-31
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   Ganu Mohini A, 2011, J Assoc Physicians India, V59, P83
   Haanpaa M, 2011, PAIN, V152, P14, DOI 10.1016/j.pain.2010.07.031
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   Javelle E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003603
   Malvy D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-200
   Ministry of Water Irrigation and Electricity, 2015, FEBR CHIK MAN CLIN, P1
   Moro ML, 2012, J INFECTION, V65, P165, DOI 10.1016/j.jinf.2012.04.005
   Ng LFP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004261
   Organizacion Panamericana de la Salud (OPS), 2011, PREP RESP ANT EV INT, P1
   Padmakumar B, 2009, INDIAN J RHEUMATOL, V4, P94, DOI DOI 10.1016/S0973-3698(10)60189-6
   Pandya S., 2008, INDIAN J RHEUMATOL, V3, P93, DOI DOI 10.1016/S0973-3698(10)60125-2
   Ramachandran V, 2014, J POSTGRAD MED, V60, P3, DOI 10.4103/0022-3859.128795
   Rosario V, 2015, CLIN RHEUMATOL, V34, P1285, DOI 10.1007/s10067-015-2979-x
   Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137
   Simon F, 2015, MED MALADIES INFECT, V45, P243, DOI 10.1016/j.medmal.2015.05.007
   Sousa Fátima Aparecida Emm Faleiros, 2002, Rev. Latino-Am. Enfermagem, V10, P446, DOI 10.1590/S0104-11692002000300020
   Staikowsky F, 2008, EPIDEMIOL INFECT, V136, P196, DOI 10.1017/S0950268807008424
   Thiberville SD, 2013, ANTIVIR RES, V99, P345, DOI 10.1016/j.antiviral.2013.06.009
   Waymouth HE, 2013, SEMIN ARTHRITIS RHEU, V43, P273, DOI 10.1016/j.semarthrit.2013.03.003
   World Health Organisation, 2009, GLOB HLTH RISKS MORT, P1
   Yaseen HM, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-249
NR 32
TC 20
Z9 21
U1 1
U2 5
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD NOV-DEC
PY 2016
VL 49
IS 6
BP 668
EP 679
DI 10.1590/0037-8682-0279-2016
PG 12
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA EH4CU
UT WOS:000391719400002
PM 28001212
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Falcao, MB
   Cimerman, S
   Luz, KG
   Chebabo, A
   Brigido, HA
   Lobo, IM
   Timerman, A
   Angerami, RN
   da Cunha, CA
   Bacha, HA
   Alves, JR
   Barbosa, AN
   Teixeira, RF
   Weissmann, L
   Oliveira, PR
   Cyrillo, MA
   Bandeira, AC
AF Falcao, Melissa Barreto
   Cimerman, Sergio
   Luz, Kleber Giovanni
   Chebabo, Alberto
   Brigido, Helena Andrade
   Lobo, Iza Maria
   Timerman, Artur
   Angerami, Rodrigo Nogueira
   da Cunha, Clovis Arns
   Bacha, Helio Arthur
   Alves, Jesse Reis
   Barbosa, Alexandre Naime
   Teixeira, Ralcyon Francis
   Weissmann, Leonardo
   Oliveira, Priscila Rosalba
   Cyrillo, Marco Antonio
   Bandeira, Antonio Carlos
TI Management of infection by the Zika virus
SO ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS
LA English
DT Review
DE Zika virus infection; Guideline; Diagnosis; Therapeutics
ID FRENCH-POLYNESIA; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; STATES; BRAZIL
AB A panel of national experts was convened by the Brazilian Infectious Diseases Society in order to organize the national recommendations for the management of zika virus infection. The focus of this document is the diagnosis, both clinical and laboratorial, and appropriate treatment of the diverse manifestations of this infection, ranging from acute mild disease to Guillain-Barre syndrome and also microcephaly and congenital malformations.
C1 [Falcao, Melissa Barreto] Univ Estadual Feira de Santana, Ave Transnordestina S-N, BR-44036900 Feira De Santana, BA, Brazil.
   [Cimerman, Sergio; Alves, Jesse Reis; Teixeira, Ralcyon Francis; Weissmann, Leonardo] Inst Infectol Emilio Ribas, Ave Doutor Arnaldo 165, BR-01246000 Sao Paulo, SP, Brazil.
   [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Rua Conego Monte S-N, BR-59037170 Natal, RN, Brazil.
   [Chebabo, Alberto] Univ Fed Rio de Janeiro, Ave Prof Rodolpho Paulo Rocco 255,50 Andar, BR-21941913 Rio De Janeiro, RJ, Brazil.
   [Brigido, Helena Andrade] Fed Univ Para, Rua Mundurucus S-N, BR-66060060 Belem, Para, Brazil.
   [Lobo, Iza Maria] Univ Fed Sergipe, Ave Claudio Batista S-N,30 Andar, BR-49060100 Aracaju, SE, Brazil.
   [Timerman, Artur] Hosp Prof Edmundo Vasconcelos, Rua Borges Lagoa 1450, BR-04038905 Sao Paulo, SP, Brazil.
   [Angerami, Rodrigo Nogueira] Univ Estadual Campinas, Rua Alexander Fleming 181, BR-13083970 Campinas, SP, Brazil.
   [da Cunha, Clovis Arns] Univ Fed Parana, Rua Gen Carneiro 181, BR-80060900 Curitiba, Parana, Brazil.
   [Bacha, Helio Arthur] Hosp Israelita Albert Einstein, Ave Albert Einstein 627,Bloco A1,Sala 220, BR-05651901 Sao Paulo, SP, Brazil.
   [Oliveira, Priscila Rosalba] Univ Sao Paulo, Rua Doutor Ovidio Pires Campos 333, BR-05403010 Sao Paulo, SP, Brazil.
   [Cyrillo, Marco Antonio] Hosp Servidor Publ Municipal, Rua Castro Alves 60, BR-01532000 Sao Paulo, SP, Brazil.
   [Bandeira, Antonio Carlos] Hosp Alianca, R Juracy Magalhaes Jr 2096, BR-41920000 Salvador, BA, Brazil.
RP Oliveira, PR (corresponding author), Univ Sao Paulo, Rua Doutor Ovidio Pires Campos 333, BR-05403010 Sao Paulo, SP, Brazil.
EM priscila.rosalba@hc.fm.usp.br
RI Angerami, Rodrigo Nogueira/A-8926-2013; Oliveira, Priscila
   Rosalba/J-7531-2012; Weissmann, Leonardo/S-4605-2019; Bacha, Helio
   Arthur/AAU-8306-2020; CIMERMAN, SERGIO/I-4981-2014; Barbosa, Alexandre
   Naime/F-5668-2012
OI Angerami, Rodrigo Nogueira/0000-0002-4976-9238; Oliveira, Priscila
   Rosalba/0000-0003-1377-6556; Weissmann, Leonardo/0000-0002-4702-3221;
   Bacha, Helio Arthur/0000-0003-4269-0065; CIMERMAN,
   SERGIO/0000-0003-4040-220X; Barbosa, Alexandre Naime/0000-0002-2187-4722
CR [Anonymous], 2016, BRAZIL REPORTS ZIKA
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Brasil Ministerio da Saude, 2015, PROT VIG RESP OC MIC
   BRASIL. Ministerio da Saude, 2016, PROT VIG RESP OC MIC
   BRASIL. Ministerio da Saude, 2016, NOT INF
   Brasil P, 2016, NEW ENGL J MED, DOI [10.1056/nejmMoa1602412, DOI 10.1056/NEJMMOA1602412]
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Centers for Disease Control and Prevention, ZIK VIR SYMPT DIAGN
   Centers for Disease Control and Prevention, ZIK VIR TRANSM
   De Noronha L, 2015, MEM I O CRUZ RIO DE, V110, P569
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00624-3
   European Centre for Disease Prevention and Control, 2015, RAP RISK ASS ZIK VIR
   Federacao Brasileira das Associacoes de Ginecologia e Obstetricia, 2016, OR REC FEBRASGO INF
   Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Kleber de Oliveira Wanderson, 2016, MMWR Morb Mortal Wkly Rep, V65, P242, DOI 10.15585/mmwr.mm6509e2
   LaBeaud AD, 2016, ZIKA VIRUS INFECT OV
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Oehler E., 2014, Eurosurveillance, V19, P20720
   Paixao ES, 2016, AM J PUBLIC HEALTH, V106, P606, DOI 10.2105/AJPH.2016.303112
   Pan American Health Organization, 2016, WHO ZIK SIT REP 21 J
   Pan American Health Organization, 2016, EP UPD NEUR SYNDR CO
   Paniz-Mondolfi AE, 2016, ANN CLIN MICROB ANTI, V15, DOI 10.1186/s12941-016-0157-x
   Parreira R, 2013, CHIKUNGUNIYA ZIKA VI, V54, P9
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1
   Rabe IB, 2016, MMWR MORB MORTAL REP, DOI 10.15585/mmwr.mm6521e1
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Rodriguez-Morales AJ, 2015, ARCH MED, V11
   Rodriguez-Morales AJ, 2016, ANN CLIN MICROB ANTI, V15, DOI 10.1186/s12941-016-0128-2
   Rodriguez-Morales AJ, 2016, TRAVEL MED INFECT DI, V14, P5, DOI 10.1016/j.tmaid.2016.01.011
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Silvia Sardi, 2016, J CLIN MICROBIOL, DOI [10.1128/JCM.00877-16, DOI 10.1128/JCM.00877-16]
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Villamil-Gomez WE, 2016, J INFECT PUBLIC HEAL, V9, P684, DOI 10.1016/j.jiph.2015.12.002
   Villar J, 2016, LANCET, V387, P844, DOI 10.1016/S0140-6736(16)00384-6
   World Health Organization, ZIK VIR MICR GUILL B
   World Health Organization-, ID MAN GUILL BARR SY
   World Health Organization, GUILL BARR SYNDR BRA
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 56
TC 13
Z9 13
U1 0
U2 67
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-0711
J9 ANN CLIN MICROB ANTI
JI Ann. Clin. Microbiol. Antimicrob.
PD SEP 29
PY 2016
VL 15
AR 57
DI 10.1186/s12941-016-0172-y
PG 15
WC Microbiology
SC Microbiology
GA DX4QR
UT WOS:000384366700001
PM 27686610
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Martines, RB
   Bhatnagar, J
   Ramos, AMD
   Davi, HPF
   Iglezias, SD
   Kanamura, CT
   Keating, MK
   Hale, G
   Silva-Flannery, L
   Muehlenbachs, A
   Ritter, J
   Gary, J
   Rollin, D
   Goldsmith, CS
   Reagan-Steiner, S
   Ermias, Y
   Suzuki, T
   Luz, KG
   de Oliveira, WK
   Lanciotti, R
   Lambert, A
   Shieh, WJ
   Zaki, SR
AF Martines, Roosecelis Brasil
   Bhatnagar, Julu
   de Oliveira Ramos, Ana Maria
   Freire Davi, Helaine Pompeia
   Iglezias, Silvia D'Andretta
   Kanamura, Cristina Takami
   Keating, M. Kelly
   Hale, Gillian
   Silva-Flannery, Luciana
   Muehlenbachs, Atis
   Ritter, Jana
   Gary, Joy
   Rollin, Dominique
   Goldsmith, Cynthia S.
   Reagan-Steiner, Sarah
   Ermias, Yokabed
   Suzuki, Tadaki
   Luz, Kleber G.
   de Oliveira, Wanderson Kleber
   Lanciotti, Robert
   Lambert, Amy
   Shieh, Wun-Ju
   Zaki, Sherif R.
TI Pathology of congenital Zika syndrome in Brazil: a case series
SO LANCET
LA English
DT Article
ID VIRUS-INFECTION; ARTHROGRYPOSIS; ETIOLOGY; TISSUES; UPDATE; STATES;
   BRAIN; PCR
AB Background Zika virus is an arthropod-borne virus that is a member of the family Flaviviridae transmitted mainly by mosquitoes of the genus Aedes. Although usually asymptomatic, infection can result in a mild and self-limiting illness characterised by fever, rash, arthralgia, and conjunctivitis. An increase in the number of children born with microcephaly was noted in 2015 in regions of Brazil with high transmission of Zika virus. More recently, evidence has been accumulating supporting a link between Zika virus and microcephaly. Here, we describe findings from three fatal cases and two spontaneous abortions associated with Zika virus infection.
   Methods In this case series, formalin-fixed paraffin-embedded tissue samples from five cases, including two newborn babies with microcephaly and severe arthrogryposis who died shortly after birth, one 2-month-old baby, and two placentas from spontaneous abortions, from Brazil were submitted to the Infectious Diseases Pathology Branch at the US Centers for Disease Control and Prevention (Atlanta, GA, USA) between December, 2015, and March, 2016. Specimens were assessed by histopathological examination, immunohistochemical assays using a mouse anti-Zika virus antibody, and RT-PCR assays targeting the NS5 and envelope genes. Amplicons of RT-PCR positive cases were sequenced for characterisation of strains.
   Findings Viral antigens were localised to glial cells and neurons and associated with microcalcifications in all three fatal cases with microcephaly. Antigens were also seen in chorionic villi of one of the first trimester placentas. Tissues from all five cases were positive for Zika virus RNA by RT-PCR, and sequence analyses showed highest identities with Zika virus strains isolated from Brazil during 2015.
   Interpretation These findings provide strong evidence of a link between Zika virus infection and different congenital central nervous system malformations, including microcephaly as well as arthrogryposis and spontaneous abortions.
C1 [Martines, Roosecelis Brasil; Bhatnagar, Julu; Keating, M. Kelly; Hale, Gillian; Silva-Flannery, Luciana; Muehlenbachs, Atis; Ritter, Jana; Gary, Joy; Rollin, Dominique; Goldsmith, Cynthia S.; Ermias, Yokabed; Shieh, Wun-Ju; Zaki, Sherif R.] NCEZID, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA USA.
   [Reagan-Steiner, Sarah] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA.
   [de Oliveira Ramos, Ana Maria] Univ Fed Rio Grande do Norte, Dept Pathol, Natal, RN, Brazil.
   [de Oliveira Ramos, Ana Maria; Freire Davi, Helaine Pompeia] Serv Ascertaining Death State Rio Grande Norte SV, Natal, RN, Brazil.
   [Iglezias, Silvia D'Andretta; Kanamura, Cristina Takami] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Suzuki, Tadaki] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan.
   [Luz, Kleber G.] Univ Fed Rio Grande do Norte, Dept Infect Dis, Natal, RN, Brazil.
   [de Oliveira, Wanderson Kleber] Minist Hlth, Brasilia, DF, Brazil.
   [Lanciotti, Robert; Lambert, Amy] Ctr Dis Control & Prevent, NCEZID, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO USA.
RP Zaki, SR (corresponding author), Ctr Dis Control & Prevent, NCEZID, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA 30329 USA.
EM szaki@cdc.gov
RI Oliveira, Wanderson/AAF-5182-2019
OI Oliveira, Wanderson/0000-0002-9662-1930; Ramos, Ana
   Maria/0000-0001-7542-4973; Kanamura, Cristina/0000-0003-2537-2356
CR Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Bhatnagar J, 2016, 32 CLIN VIR S
   Bhatnagar J, 2012, AM J TROP MED HYG, V86, P335, DOI 10.4269/ajtmh.2012.11-0346
   Callahan JD, 2001, J CLIN MICROBIOL, V39, P4119, DOI 10.1128/JCM.39.11.4119-4124.2001
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Franca GV, 2016, LANCET
   FRASER SH, 1994, J PAEDIATR CHILD H, V30, P450, DOI 10.1111/j.1440-1754.1994.tb00701.x
   Gabrielli L, 2012, CLIN MICROBIOL INFEC, V18, pE419, DOI 10.1111/j.1469-0691.2012.03983.x
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Hall JG, 2014, EUR J MED GENET, V57, P464, DOI 10.1016/j.ejmg.2014.03.008
   Jouannic JM, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00625-5
   Kowalczyk B, 2016, ARCH MED SCI, V12, P10, DOI 10.5114/aoms.2016.57578
   Lazar M, 2016, EBIOMEDICINE, V3, P86, DOI 10.1016/j.ebiom.2015.11.050
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   McDonagh S, 2004, J INFECT DIS, V190, P826, DOI 10.1086/422330
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Oehler E, 2014, EUROSURVEILLANCE, V19, P4
   PASTUSZAK AL, 1994, NEW ENGL J MED, V330, P901, DOI 10.1056/NEJM199403313301305
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Silasi M, 2015, AM J REPROD IMMUNOL, V73, P199, DOI 10.1111/aji.12355
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 29
TC 175
Z9 179
U1 2
U2 96
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 27
PY 2016
VL 388
IS 10047
BP 898
EP 904
DI 10.1016/S0140-6736(16)30883-2
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU0RI
UT WOS:000381911800028
PM 27372395
OA Bronze
DA 2020-12-15
ER

PT J
AU de Noronha, L
   Zanluca, C
   Azevedo, MLV
   Luz, KG
   dos Santos, CND
AF de Noronha, Lucia
   Zanluca, Camila
   Viola Azevedo, Marina Luize
   Luz, Kleber Giovanni
   Duarte dos Santos, Claudia Nunes
TI Zika virus damages the human placental barrier and presents marked fetal
   neurotropism
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Zika virus; transplacental transmission; Hofbauer cells; neurotropism
ID WEST-NILE VIRUS; INFECTIONS; TRANSMISSION; PATHOGENESIS; EMERGENCE
AB An unusually high incidence of microcephaly in newborns has recently been observed in Brazil. There is a temporal association between the increase in cases of microcephaly and the Zika virus (ZIKV) epidemic. Viral RNA has been detected in amniotic fluid samples, placental tissues and newborn and fetal brain tissues. However, much remains to be determined concerning the association between ZIKV infection and fetal malformations. In this study, we provide evidence of the transplacental transmission of ZIKV through the detection of viral proteins and viral RNA in placental tissue samples from expectant mothers infected at different stages of gestation. We observed chronic placentitis (TORCH type) with viral protein detection by immunohistochemistry in Hofbauer cells and some histiocytes in the intervillous spaces. We also demonstrated the neurotropism of the virus via the detection of viral proteins in glial cells and in some endothelial cells and the observation of scattered foci of microcalcifications in the brain tissues. Lesions were mainly located in the white matter. ZIKV RNA was also detected in these tissues by real-time-polymerase chain reaction. We believe that these findings will contribute to the body of knowledge of the mechanisms of ZIKV transmission, interactions between the virus and host cells and viral tropism.
C1 [de Noronha, Lucia; Viola Azevedo, Marina Luize] Pontificia Univ Catolica Parana, Curitiba, Parana, Brazil.
   [Zanluca, Camila; Duarte dos Santos, Claudia Nunes] Fundacao Oswaldo Cruz, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
   [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Inst Med Trop, BR-59072970 Natal, RN, Brazil.
RP dos Santos, CND (corresponding author), Fundacao Oswaldo Cruz, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
EM clsantos@fiocruz.br
RI Santos, Claudia Duarte dos/P-4868-2019; Duarte dos Santos,
   Claudia/E-1857-2018; noronha, lucia/F-6339-2015
OI Santos, Claudia Duarte dos/0000-0001-8707-6638; Duarte dos Santos,
   Claudia/0000-0001-8707-6638; noronha, lucia/0000-0003-0310-7164;
   Zanluca, Camila/0000-0001-7350-9105
FU FIOCRUZ; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPESCAPES; Fundacao AraucariaFundacao Araucaria
FX FIOCRUZ, CNPq, CAPES, Fundacao Araucaria. LN and CZ contributed equally
   to this work.
CR Alpert SG, 2003, AM J OPHTHALMOL, V136, P733, DOI 10.1016/S0002-9394(03)00452-5
   Baurakiades E, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-101
   Benirchke K, 2006, PATHOLOGY HUMAN PLAC, P502
   Boussemart T, 2001, J Perinatol, V21, P255, DOI 10.1038/sj.jp.7200530
   Brasil P., 2016, N ENGL J ME IN PRESS
   Calvet G, 2016, LANCET INFECT DIS
   Chong DC, 2009, PEDIATR DEVEL PATHOL, V12, P211, DOI 10.2350/07-02-0229.1
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   EBC - Empresa Brasil de Comunicacao, 2016, CAS CONF MICR SOB PA
   GREENOUGH A, 1994, ARCH DIS CHILD-FETAL, V70, pF163, DOI 10.1136/fn.70.3.F163
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hollidge BS, 2010, J NEUROIMMUNE PHARM, V5, P428, DOI 10.1007/s11481-010-9234-7
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Kim CJ, 2015, AM J OBSTET GYNECOL, V213, pS53, DOI 10.1016/j.ajog.2015.08.041
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Laszczyk Magdalena, 2007, Ginekol Pol, V78, P560
   Love S, 2002, GREENFIELDS NEUROPAT, P45
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P1, DOI [DOI 10.15585/MMWR.MM6506E1ER, 10.15585/mmwr.mm6506e1]
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Misra UK, 2010, PROG NEUROBIOL, V91, P108, DOI 10.1016/j.pneurobio.2010.01.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Murray KO, 2010, VET RES, V41, DOI 10.1051/vetres/2010039
   Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001
   Oehler E, 2014, EUROSURVEILLANCE, V19, P4
   Pan American Health Organization (PAHO), 2016, ZIK VIR INF
   Piersen TC, 2013, FIELDS VIROLOGY, P747
   Poersch CD, 2005, J CLIN VIROL, V32, P272, DOI 10.1016/j.jcv.2004.08.008
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   TSAI TF, 1993, J INFECT DIS, V168, P1520, DOI 10.1093/infdis/168.6.1520
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 31
TC 129
Z9 134
U1 0
U2 41
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY
PY 2016
VL 111
IS 5
BP 287
EP +
DI 10.1590/0074-02760160085
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DN2EI
UT WOS:000376876500002
PM 27143490
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Rezende, NCC
   Bezerra, CLPAM
   de Almeida, JJS
   Fernandes, TUG
   Luz, KG
AF Cavalcante Rezende, Natania Carol
   Alves Madeira Bezerra, Camila Loredana Pereira
   Salviano de Almeida, Jessica Jacinto
   Gomes Fernandes, Tatiane Uetti
   Luz, Kleber Giovanni
TI Secondary transmission of cryptosporidiosis associated with well water
   consumption: two case studies
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Cryptosporidium spp; Well water; Diarrhea
ID AGE
AB Cryptosporidiosis is a very prominent disease in the field of public health, and usually causes diarrhea. We describe two immunocompetent patients who presented with chronic diarrhea that was ultimately found to be caused by continuous exposure to well water contaminated with the microbial cysts (oocysts) of the Cryptosporidium spp parasite. We describe the patients' histories and possible explanations for their prolonged symptoms.
C1 [Cavalcante Rezende, Natania Carol; Alves Madeira Bezerra, Camila Loredana Pereira; Salviano de Almeida, Jessica Jacinto; Gomes Fernandes, Tatiane Uetti] Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, BR-59072970 Natal, RN, Brazil.
   [Luz, Kleber Giovanni] Inst Med Trop Rio Grande Norte, Natal, RN, Brazil.
RP Rezende, NCC (corresponding author), Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, BR-59072970 Natal, RN, Brazil.
EM carolcavalcante.r@gmail.com
CR Alves CJ, 2007, REV BRAS PSIQUIATR, V29, P363
   Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170
   Garlipp C. R., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P467, DOI 10.1590/S0036-46651995000500014
   Haynes L, 2009, CURR OPIN IMMUNOL, V21, P414, DOI 10.1016/j.coi.2009.05.009
   Lima Erilane de Castro, 2003, Ciênc. saúde coletiva, V8, P791
   Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446
   Ogawa T, 2000, MECH AGEING DEV, V117, P57, DOI 10.1016/S0047-6374(00)00137-8
   Plowden J, 2004, AGING CELL, V3, P161, DOI 10.1111/j.1474-9728.2004.00102.x
   Vismari L, 2008, REV PSIQ CLIN-BRAZIL, V35, P196
   WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002
NR 10
TC 0
Z9 0
U1 0
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD MAR-APR
PY 2016
VL 49
IS 2
BP 260
EP 262
DI 10.1590/0037-8682-0232-2015
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DM9AU
UT WOS:000376656800021
PM 27192601
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Martines, RB
   Bhatnagar, J
   Keating, MK
   Silva-Flannery, L
   Muehlenbachs, A
   Gary, J
   Goldsmith, C
   Hale, G
   Ritter, J
   Rollin, D
   Shieh, WJ
   Luz, KG
   Ramos, AMDO
   Davi, HPF
   de Oliveria, WK
   Lanciotti, R
   Lambert, A
   Zaki, S
AF Martines, Roosecelis Brasil
   Bhatnagar, Julu
   Keating, M. Kelly
   Silva-Flannery, Luciana
   Muehlenbachs, Atis
   Gary, Joy
   Goldsmith, Cynthia
   Hale, Gillian
   Ritter, Jana
   Rollin, Dominique
   Shieh, Wun-Ju
   Luz, Kleber G.
   de Oliveira Ramos, Ana Maria
   Freire Davi, Helaine Pompeia
   de Oliveria, Wanderson Kleber
   Lanciotti, Robert
   Lambert, Amy
   Zaki, Sherif
TI Evidence of Zika Virus Infection in Brain and Placental Tissues from Two
   Congenitally Infected Newborns and Two Fetal Losses - Brazil, 2015
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Martines, Roosecelis Brasil; Bhatnagar, Julu; Keating, M. Kelly; Silva-Flannery, Luciana; Muehlenbachs, Atis; Gary, Joy; Goldsmith, Cynthia; Hale, Gillian; Ritter, Jana; Rollin, Dominique; Shieh, Wun-Ju; Zaki, Sherif] CDC, Infectious Dis Pathol Branch, Div High Consequence Pathogens & Pathol, NCEZID, Atlanta, GA 30333 USA.
   [Luz, Kleber G.] Univ Fed Rio Grande do Norte, Dept Infect Dis, BR-59072970 Natal, RN, Brazil.
   [de Oliveira Ramos, Ana Maria] Univ Fed Rio Grande do Norte, Dept Pathol, BR-59072970 Natal, RN, Brazil.
   [Freire Davi, Helaine Pompeia] Serv Ascertaining Death State Rio Grande do Nort, Natal, RN, Brazil.
   [de Oliveria, Wanderson Kleber] Minist Hlth, Sao Paulo, Brazil.
   [Lanciotti, Robert; Lambert, Amy] CDC, Arboviral Dis Branch, Div Vector Borne Dis, NCEZID, Atlanta, GA 30333 USA.
RP Martines, RB (corresponding author), CDC, Infectious Dis Pathol Branch, Div High Consequence Pathogens & Pathol, NCEZID, Atlanta, GA 30333 USA.
EM RBrasilMartines@cdc.gov
RI Oliveira, Wanderson/D-7140-2016
OI Oliveira, Wanderson/0000-0002-9662-1930
CR Bhatnagar J, 2012, AM J TROP MED HYG, V86, P335, DOI 10.4269/ajtmh.2012.11-0346
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Victoria CG, 2016, LANCET
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 5
TC 280
Z9 281
U1 0
U2 51
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD FEB 19
PY 2016
VL 65
IS 6
BP 159
EP 160
DI 10.15585/mmwr.mm6506e1
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DF4TY
UT WOS:000371345000005
OA Bronze
DA 2020-12-15
ER

PT J
AU Pinto, VL
   Luz, K
   Parreira, R
   Ferrinho, P
AF Pinto Junior, Vitor Laerte
   Luz, Kleber
   Parreira, Ricardo
   Ferrinho, Paulo
TI Zika Virus: A Review to Clinicians
SO ACTA MEDICA PORTUGUESA
LA Portuguese
DT Article
DE Aedes; Arboviruses; Flavivirus; Flaviviridae Infections
ID YELLOW-FEVER; INFECTIONS; TRANSMISSION; EPIDEMIC; NIGERIA; STATE
AB Zika virus is a flavivirus related to Dengue virus, yellow fever virus and West Nile virus. It is considered an emerging arbovirus transmitted by mosquitos of the genus Aedes. Its first description took place in 1947 in the Zika Forest in Uganda, isolated on Rhesus monkey used as bait to study the yellow fever virus. Sporadic cases have been detected in African countries and at the end of the 70's in Indonesia. In 2007, epidemics were described in Micronesia and other islands in the Pacific Ocean and more recently in Brazil. Clinical picture is characterized as a 'dengue-like' syndrome, with abrupt onset of fever and an early onset evanescent rash, often pruritic. Occasionally the disease has been associated with Guillain-Barre syndrome. Nevertheless, until now deaths and complications caused by the disease were not reported. The diagnosis can be performed by PCR or by IgG and IgM antibodies detection. The rapid spread of the virus and its epidemic potential are especially problematic in countries where there are the circulation of other arboviruses which imposes difficulties in the differential diagnosis and healthcare burden. Control measures are the same recommended for dengue and chikungunya which are based in health education and vector control.
C1 [Pinto Junior, Vitor Laerte] Fiocruz MS, Dept Epidemiol & Vigilancia Saude, Brasilia, DF, Brazil.
   [Pinto Junior, Vitor Laerte; Parreira, Ricardo; Ferrinho, Paulo] Univ Nova Lisboa, Inst Higiene & Med Trop, Global Hlth & Trop Med, P-1200 Lisbon, Portugal.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, Inst Med Trop Rio Grande do Norte, Dept Doencas Infecciosas, BR-59072970 Natal, RN, Brazil.
RP Pinto, VL (corresponding author), Fiocruz MS, Dept Epidemiol & Vigilancia Saude, Brasilia, DF, Brazil.
EM vitorlaerte@gmail.com
RI Parreira, Ricardo/AAH-4559-2019; Parreira, Ricardo/I-2304-2012; Pinto
   Junior, Vitor Laerte/O-9405-2014; Ferrinho, Paulo/J-2835-2012
OI Parreira, Ricardo/0000-0002-4832-9898; Parreira,
   Ricardo/0000-0002-4832-9898; Pinto Junior, Vitor
   Laerte/0000-0003-0556-5310; Ferrinho, Paulo/0000-0002-3722-0803
CR Ansar V, 2015, PRIMARY CARE, V42, P189, DOI 10.1016/j.pop.2015.01.001
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Chippaux A, 1981, Med Trop (Mars), V41, P53
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1953, T ROY SOC TROP MED H, V47, P13, DOI 10.1016/0035-9203(53)90021-2
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   European Centre for Disease Prevention and Control, RAP RISK ASS ZIK VIR
   FAGBAMI A, 1977, TROP GEOGR MED, V29, P187
   FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fonseca K, 2014, AM J TROP MED HYG, V91, P1035, DOI 10.4269/ajtmh.14-0151
   GESER A, 1970, Bulletin of the World Health Organization, V43, P539
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   JAN C, 1978, B SOC PATHOL EXOT, V71, P140
   Keighley CL, 2015, CURR OPIN INFECT DIS, V28, P139, DOI 10.1097/QCO.0000000000000145
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Ledermann JP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003188
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Mansfield KL, 2011, J GEN VIROL, V92, P2821, DOI 10.1099/vir.0.031641-0
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   MONATH TP, 1973, B WORLD HEALTH ORGAN, V49, P235
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EUROSURVEILLANCE, P19
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nelwan EJ, 2014, ACTA MED INDONES, V46, P339
   Oehler E, 2014, EURO SURVEILL, V19
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   RENAUDET J, 1978, B SOC PATHOL EXOT, V71, P131
   Robin Y., 1975, Bulletin Soc Path Exot, V68, P249
   Rudolph KE, 2014, AM J TROP MED HYG, V90, P882, DOI 10.4269/ajtmh.13-0403
   SALUZZO JF, 1981, B SOC PATHOL EXOT, V74, P490
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Summers DJ, 2015, J TRAVEL MED, V22, P338, DOI 10.1111/jtm.12208
   WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P263, DOI 10.1016/0035-9203(58)90085-3
   Zammarchi L, 2015, EUROSURVEILLANCE, V20, P14
   Zammarchi L, 2015, J CLIN VIROL, V63, P32, DOI 10.1016/j.jcv.2014.12.005
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 51
TC 31
Z9 34
U1 0
U2 87
PU ORDEM MEDICOS
PI LISBON
PA AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL
SN 1646-0758
J9 ACTA MEDICA PORT
JI Acta Medica Port.
PD NOV-DEC
PY 2015
VL 28
IS 6
BP 760
EP 765
DI 10.20344/amp.6929
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA DB5AZ
UT WOS:000368526700015
PM 26849762
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Luz, KG
   dos Santos, GIV
   Vieira, RD
AF Luz, Kleber Giovanni
   Viana dos Santos, Glauco Igor
   Vieira, Renata de Magalhaes
TI Zika Virus Fever
SO EPIDEMIOLOGIA E SERVICOS DE SAUDE
LA Portuguese
DT Editorial Material
C1 [Luz, Kleber Giovanni; Viana dos Santos, Glauco Igor; Vieira, Renata de Magalhaes] Univ Fed Rio Grande do Norte, Inst Med Trop, Natal, RN, Brazil.
RP Luz, KG (corresponding author), Rua Conego Monte 110, BR-59037170 Natal, RN, Brazil.
EM klebergluz@gmail.com
CR [Anonymous], 1997, SDF, VL 50/28
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Ministerio da Saude (BR), 2015, 1 MIN SAUD BR
   Ministerio de Saude (MS), 2015, B EPIDEMIOL, V46, P1
   Musso D, 2015, LANCET, V386, P243, DOI 10.1016/S0140-6736(15)61273-9
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 10
TC 9
Z9 11
U1 0
U2 0
PU MINISTERIO DA SAUDE
PI BRASILIA
PA ESPLANADA MINISTERIOS, BLOCO G, BRASILIA, DF 70058-900, BRAZIL
SN 1679-4974
EI 2237-9622
J9 EPIDEMIOL SERV SAUDE
JI Epidemiol. Serv. Saude
PD OCT-DEC
PY 2015
VL 24
IS 4
BP 785
EP 788
DI 10.5123/S1679-49742015000400021
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA VE5VK
UT WOS:000439661700021
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Dayan, G
   Arredondo, JL
   Carrasquilla, G
   Deseda, CC
   Dietze, R
   Luz, K
   Costa, MSN
   Cunha, RV
   Rey, LC
   Morales, J
   Reynales, H
   Miranda, M
   Zambrano, B
   Rivas, E
   Garbes, P
   Noriega, F
AF Dayan, Gustavo
   Arredondo, Jose L.
   Carrasquilla, Gabriel
   Deseda, Carmen C.
   Dietze, Reynaldo
   Luz, Kleber
   Costa, Maria Selma N.
   Cunha, Rivaldo V.
   Rey, Luis C.
   Morales, Javier
   Reynales, Humberto
   Miranda, Maria
   Zambrano, Betzana
   Rivas, Enrique
   Garbes, Pedro
   Noriega, Fernando
TI Prospective Cohort Study with Active Surveillance for Fever in Four
   Dengue Endemic Countries in Latin America
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ADJUSTED LIFE YEARS; ECONOMIC-IMPACT; TYPE-2 VIRUS; PUERTO-RICO; NS1
   ELISA; PHASE-II; VACCINE; SAFETY; IMMUNOGENICITY; RECOMBINANT
AB To prepare for a Phase III dengue vaccine efficacy trial, 20 investigational sites were selected for this observational study to identify dengue infections in a closed cohort (N = 3,000 children 9-16 years of age). Of 255 acute febrile episodes experienced by 235 children, 50 (21.3%) were considered serologically probable dengue, and 18 (7.7%) were considered virologically confirmed (i.e., dengue NS1 antigen positive) dengue cases. Considering the disease-free and at-risk period from study start to onset of symptoms, the overall incidence density of acute febrile episodes was 17.7 per 1100 person-years of follow-up, ranging from 15.3 in Colombia to 22.0 in Puerto Rico. This study showed that all sites were capable of capturing and following up acute febrile episodes within a specific timeframe among the established cohort and to detect dengue cases.
C1 Sanofi Pasteur, Clin Res & Dev, Sao Paulo, Brazil.
   [Arredondo, Jose L.] Inst Nacl Pediat, Unidad Apoyo Invest Clin, Insurgentes Cuicuilco, Mexico City, DF, Mexico.
   [Carrasquilla, Gabriel] Fdn Santa Fe Bogota, Ctr Estudios Invest Salud, Bogota, Colombia.
   [Deseda, Carmen C.] Caribbean Travel Med Clin, San Juan, PR USA.
   [Dietze, Reynaldo] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, CBM UFES, Vitoria, ES, Brazil.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, Hosp Infanta Varela Santiago, BR-59072970 Natal, RN, Brazil.
   Univ Fed Goias, Univ Hosp, Goiania, Go, Brazil.
   Univ Fed Mato Grosso do Sul, Univ Hosp, Campo Grande, MS, Brazil.
   [Rey, Luis C.] Univ Fed Ceara, Unidade Pesquisas Clin, Inst Biomed, IBIMED, Fortaleza, Ceara, Brazil.
   Clin Res Puerto Rico, Guayama, PR USA.
   [Reynales, Humberto] Ctr Atenc Invest Med, Bogota, Colombia.
   Sanofi Pasteur, Clin Res & Dev, Bogota, Colombia.
   Sanofi Pasteur, Clin Res & Dev, Montevideo, Uruguay.
   Sanofi Pasteur, Clin Res & Dev, Mexico City, DF, Mexico.
   [Dayan, Gustavo; Noriega, Fernando] Sanofi Pasteur, Clin Res & Dev, Swiftwater, PA USA.
RP Rivas, E (corresponding author), Av Univ 1738, Mexico City 04000, DF, Mexico.
EM gustavo.dayan@sanofipasteur.com; arredondo.joseluis@gmail.com;
   Gabriel.Carrasquilla@fsfb.org.co; desedamd@hotmail.com;
   rdietze@ndi.ufes.br; klebergluz@gmail.com; m.selma@uol.com.br;
   rivaldo_venancio@uol.com.br; reyluisc@gmail.com;
   crpr@clinicalresearchpr.com; humberto.reynales@caimed.com;
   mariaconsuelo.miranda@sanofipasteur.com;
   betzana.zambrano@sanofipasteur.com; Enrique.Rivas@sanofipasteur.com;
   pedro.garbes@sanofipasteur.com; fernando.noriega@sanaipasteur.com
OI Dietze, Reynaldo/0000-0002-6995-8001; Arredondo-Garcia, Jose
   Luis/0000-0001-6560-046X; Miranda Montoya, Maria
   Consuelo/0000-0001-5730-0723
FU Sanofi-Pasteur
FX This study was sponsored by Sanofi-Pasteur.
CR Armien B, 2008, AM J TROP MED HYG, V79, P364, DOI 10.4269/ajtmh.2008.79.364
   Barclay E, 2008, LANCET, V371, P973, DOI 10.1016/S0140-6736(08)60435-3
   Blacksell SD, 2006, CLIN INFECT DIS, V42, P1127, DOI 10.1086/501358
   Camacho Tania, 2004, Biomédica, V24, P174
   Capeding RZ, 2011, VACCINE, V29, P3863, DOI 10.1016/j.vaccine.2011.03.057
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986
   Coller BAG, 2011, CURR OPIN IMMUNOL, V23, P391, DOI 10.1016/j.coi.2011.03.005
   Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
   Gubler D. J., 2002, Dengue Bulletin, V26, P96
   Guirakhoo F, 2000, J VIROL, V74, P5477, DOI 10.1128/JVI.74.12.5477-5485.2000
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Guirakhoo F, 2006, HUM VACCINES, V2, P60, DOI 10.4161/hv.2.2.2555
   Guzman MG, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000811
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   Hunsperger EA, 2009, EMERG INFECT DIS, V15, P436, DOI 10.3201/eid1503.080923
   Hurtado-Diaz M, 2007, TROP MED INT HEALTH, V12, P1327, DOI 10.1111/j.1365-3156.2007.01930.x
   Lanata CF, 2012, VACCINE, V30, P5935, DOI 10.1016/j.vaccine.2012.07.043
   Lapphra K, 2008, DIAGN MICR INFEC DIS, V60, P387, DOI 10.1016/j.diagmicrobio.2007.11.010
   Leo YS, 2012, HUM VACC IMMUNOTHER, V8, P1259, DOI 10.4161/hv.21224
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Luz PM, 2009, TROP MED INT HEALTH, V14, P237, DOI 10.1111/j.1365-3156.2008.02203.x
   Meltzer MI, 1998, AM J TROP MED HYG, V59, P265, DOI 10.4269/ajtmh.1998.59.265
   Morrison D, 2010, J INFECT DIS, V201, P370, DOI 10.1086/649916
   Padilla J.C., 2012, DENGUE COLOMBIA EPID
   Pan American Health Organization (PAHO), 2013, DENGUE
   Poo J, 2011, PEDIATR INFECT DIS J, V30, pE9, DOI 10.1097/INF.0b013e3181fe05af
   Qiao M, 2011, AM J TROP MED HYG, V85, P724, DOI 10.4269/ajtmh.2011.10-0436
   Ramos MM, 2008, AM J TROP MED HYG, V79, P123, DOI 10.4269/ajtmh.2008.79.123
   Restrepo AC, 2014, TROP MED INT HEALTH, V19, P863, DOI 10.1111/tmi.12325
   Rothman K. J., 1998, MODERN EPIDEMIOLOGY
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sequeira M, 2011, DENGUE IN NICARAGUA
   Shepard DS, 2011, AM J TROP MED HYG, V84, P200, DOI 10.4269/ajtmh.2011.10-0503
   Standish K, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000633
   Suaya JA, 2010, HDB DIS BURDENS QUAL, P1263
   Teixeira MG, 2008, EMERG INFECT DIS, V14, P1663, DOI 10.3201/eid1410.071164
   Vaughn DW, 1999, AM J TROP MED HYG, V60, P693, DOI 10.4269/ajtmh.1999.60.693
   Villar LA, 2013, PEDIATR INFECT DIS J, V32, P1102, DOI 10.1097/INF.0b013e31829b8022
   World Health Organization, 1997, DENG HEM FEV DIAGN T
NR 39
TC 18
Z9 18
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2015
VL 93
IS 1
BP 18
EP 23
DI 10.4269/ajtmh.13-0663
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CM5YG
UT WOS:000357764300006
PM 26013373
OA Green Published, Other Gold
DA 2020-12-15
ER

PT J
AU Zanluca, C
   de Melo, VCA
   Mosimann, ALP
   dos Santos, GIV
   dos Santos, CND
   Luz, K
AF Zanluca, Camila
   Andrade de Melo, Vanessa Campos
   Pamplona Mosimann, Ana Luiza
   Viana dos Santos, Glauco Igor
   Duarte dos Santos, Claudia Nunes
   Luz, Kleber
TI First report of autochthonous transmission of Zika virus in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Zika virus; "dengue-like syndrome"; Brazil
ID CHIKUNGUNYA-VIRUS; FRENCH-POLYNESIA; DENGUE VIRUSES; PACIFIC
AB In the early 2015, several cases of patients presenting symptoms of mild fever, rash, conjunctivitis and arthralgia were reported in the northeastern Brazil. Although all patients lived in a dengue endemic area, molecular and serological diagnosis for dengue resulted negative. Chikungunya virus infection was also discarded. Subsequently, Zika virus (ZIKV) was detected by reverse transcription-polymerase chain reaction from the sera of eight patients and the result was confirmed by DNA sequencing. Phylogenetic analysis suggests that the ZIKV identified belongs to the Asian clade. This is the first report of ZIKV infection in Brazil.
C1 [Zanluca, Camila; Pamplona Mosimann, Ana Luiza; Duarte dos Santos, Claudia Nunes] Fundacao Oswaldo Cruz, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
   [Andrade de Melo, Vanessa Campos; Viana dos Santos, Glauco Igor] Secretaria Estadual Saude Rio Grande Norte, Natal, RN, Brazil.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, Inst Med Trop, BR-59072970 Natal, RN, Brazil.
RP dos Santos, CND (corresponding author), Fundacao Oswaldo Cruz, Inst Carlos Chagas, Lab Virol Mol, Curitiba, Parana, Brazil.
EM clsantos@fiocruz.br; klebergluz@gmail.com
RI Duarte dos Santos, Claudia/E-1857-2018; Mosimann, Ana Luiza
   Pamplona/AAB-4714-2019; Santos, Claudia Duarte dos/P-4868-2019
OI Duarte dos Santos, Claudia/0000-0001-8707-6638; Mosimann, Ana Luiza
   Pamplona/0000-0002-3504-5562; Santos, Claudia Duarte
   dos/0000-0001-8707-6638; Zanluca, Camila/0000-0001-7350-9105
CR Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Caron M, 2012, CLIN INFECT DIS, V55, pE45, DOI 10.1093/cid/cis530
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Piersen TC, 2013, FIELDS VIROLOGY, P747
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
NR 17
TC 668
Z9 709
U1 3
U2 382
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUN
PY 2015
VL 110
IS 4
BP 569
EP 572
DI 10.1590/0074-02760150192
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CL0DT
UT WOS:000356610000017
PM 26061233
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Villar, L
   Dayan, GH
   Arredondo-Garcia, JL
   Rivera, DM
   Cunha, R
   Deseda, C
   Reynales, H
   Costa, MS
   Morales-Ramirez, JO
   Carrasquilla, G
   Rey, LC
   Dietze, R
   Luz, K
   Rivas, E
   Montoya, MCM
   Supelano, MC
   Zambrano, B
   Langevin, E
   Boaz, M
   Tornieporth, N
   Saville, M
   Noriega, F
AF Villar, Luis
   Dayan, Gustavo Horacio
   Luis Arredondo-Garcia, Jose
   Maribel Rivera, Doris
   Cunha, Rivaldo
   Deseda, Carmen
   Reynales, Humberto
   Costa, Maria Selma
   Morales-Ramirez, Javier Osvaldo
   Carrasquilla, Gabriel
   Rey, Luis Carlos
   Dietze, Reynaldo
   Luz, Kleber
   Rivas, Enrique
   Miranda Montoya, Maria Consuelo
   Cortes Supelano, Margarita
   Zambrano, Betzana
   Langevin, Edith
   Boaz, Mark
   Tornieporth, Nadia
   Saville, Melanie
   Noriega, Fernando
CA CYD15 Study Grp
TI Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PHASE-II; IMMUNOGENICITY; SAFETY; RECOMBINANT; TRIAL; CHALLENGES;
   GUIDELINES; BRAZIL; VIRUS
AB Background
   In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development.
   Methods
   In a phase 3 efficacy trial of a tetravalent dengue vaccine in five Latin American countries where dengue is endemic, we randomly assigned healthy children between the ages of 9 and 16 years in a 2: 1 ratio to receive three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo at months 0, 6, and 12 under blinded conditions. The children were then followed for 25 months. The primary outcome was vaccine efficacy against symptomatic, virologically confirmed dengue (VCD), regardless of disease severity or serotype, occurring more than 28 days after the third injection.
   Results
   A total of 20,869 healthy children received either vaccine or placebo. At baseline, 79.4% of an immunogenicity subgroup of 1944 children had seropositive status for one or more dengue serotypes. In the per-protocol population, there were 176 VCD cases (with 11,793 person-years at risk) in the vaccine group and 221 VCD cases (with 5809 person-years at risk) in the control group, for a vaccine efficacy of 60.8% (95% confidence interval [CI], 52.0 to 68.0). In the intention-to-treat population (those who received at least one injection), vaccine efficacy was 64.7% (95% CI, 58.7 to 69.8). Serotype-specific vaccine efficacy was 50.3% for serotype 1, 42.3% for serotype 2, 74.0% for serotype 3, and 77.7% for serotype 4. Among the severe VCD cases, 1 of 12 was in the vaccine group, for an intention-to-treat vaccine efficacy of 95.5%. Vaccine efficacy against hospitalization for dengue was 80.3%. The safety profile for the CYD-TDV vaccine was similar to that for placebo, with no marked difference in rates of adverse events.
   Conclusions
   The CYD-TDV dengue vaccine was efficacious against VCD and severe VCD and led to fewer hospitalizations for VCD in five Latin American countries where dengue is endemic. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01374516.)
C1 [Villar, Luis] Univ Ind Santander, Sch Med, Clin Epidemiol Unit, Bucaramanga, Colombia.
   [Reynales, Humberto] Ctr Estudios & Invest Salud, Ctr Atenc & Invest Med, Bogota, Colombia.
   [Carrasquilla, Gabriel] Fdn Santa Fe Bogota, Bogota, Colombia.
   [Miranda Montoya, Maria Consuelo; Cortes Supelano, Margarita] Sanofi Pasteur, Bogota, Colombia.
   [Dayan, Gustavo Horacio; Boaz, Mark; Noriega, Fernando] Sanofi Pasteur, Swiftwater, PA 18370 USA.
   [Luis Arredondo-Garcia, Jose] Inst Nacl Pediat, Mexico City, DF, Mexico.
   [Rivas, Enrique] Sanofi Pasteur, Mexico City, DF, Mexico.
   [Maribel Rivera, Doris] ODISH, Tegucigalpa, Honduras.
   [Cunha, Rivaldo] Fed Univ State Mato Grosso do Sul UFMS, Campo Grande, Brazil.
   [Costa, Maria Selma] S Leste Univ, Univ Fed Goias, Hosp Clin, Goiania, Go, Brazil.
   [Rey, Luis Carlos] Univ Fed Ceara, Inst Biomed, Fortaleza, Ceara, Brazil.
   [Dietze, Reynaldo] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, Ctr Ciencias Saude, Vitoria, Brazil.
   [Luz, Kleber] Univ Fed Rio Grande do Norte, BR-59072970 Natal, RN, Brazil.
   [Deseda, Carmen] Caribbean Travel Med Clin, San Juan, PR USA.
   [Morales-Ramirez, Javier Osvaldo] Clin Res Puerto Rico, San Juan, PR USA.
   [Zambrano, Betzana] Sanofi Pasteur, Montevideo, Uruguay.
   [Langevin, Edith; Tornieporth, Nadia] Sanofi Pasteur, Marcy Letoile, France.
   [Saville, Melanie] Sanofi Pasteur, Lyon, France.
RP Dayan, GH (corresponding author), Sanofi Pasteur, Discovery Dr, Swiftwater, PA 18370 USA.
EM gustavo.dayan@sanofipasteur.com
RI de Matos, Vanessa Terezinha Gubert/A-9484-2013; Paniago, Anamaria M
   M/B-7747-2012
OI de Matos, Vanessa Terezinha Gubert/0000-0002-9361-2780; Paniago,
   Anamaria M M/0000-0002-8925-7712; Dietze, Reynaldo/0000-0002-6995-8001;
   Arredondo-Garcia, Jose Luis/0000-0001-6560-046X; Miranda Montoya, Maria
   Consuelo/0000-0001-5730-0723
FU Sanofi Pasteur
FX Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01374516.
CR Boaz M., 2014, Trials in Vaccinology, V3, P127, DOI 10.1016/j.trivac.2014.07.002
   BRESLOW NE, 1987, STAT METHODS CANC RE, V2, P94
   Cafferata Maria Luisa, 2013, Value Health Reg Issues, V2, P347, DOI 10.1016/j.vhri.2013.10.002
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   da Costa VG, 2014, VACCINE, V32, P4885, DOI 10.1016/j.vaccine.2014.07.008
   Dayan GH, 2013, AM J TROP MED HYG, V89, P1058, DOI 10.4269/ajtmh.13-0304
   Dayan GH, 2013, VACCINE, V31, P5047, DOI 10.1016/j.vaccine.2013.08.088
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094
   Guzman A, 2010, INT J ANTIMICROB AG, V36, pS40, DOI 10.1016/j.ijantimicag.2010.06.018
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743
   Hombach J, 2009, J CLIN VIROL, V46, pS7, DOI 10.1016/S1386-6532(09)70287-2
   Lam SK, 2013, EXPERT REV VACCINES, V12, P995, DOI 10.1586/14760584.2013.824712
   Lanata CF, 2012, VACCINE, V30, P5935, DOI 10.1016/j.vaccine.2012.07.043
   Leo YS, 2012, HUM VACC IMMUNOTHER, V8, P1259, DOI 10.4161/hv.21224
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   McArthur MA, 2013, EXPERT REV VACCINES, V12, P933, DOI 10.1586/14760584.2013.815412
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   Poo J, 2010, PEDIAT INFECT DIS J, DOI 10.1097/INF.0b013e3181fe05af
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Shepard DS, 2011, AM J TROP MED HYG, V84, P200, DOI 10.4269/ajtmh.2011.10-0503
   Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846
   Timiryasova TM, 2013, AM J TROP MED HYG, V88, P962, DOI 10.4269/ajtmh.12-0461
   Tran NH, 2012, J VACCINES VACCIN, V3, P7, DOI [10.4172/2157-7560.1000162, DOI 10.4172/2157-7560.1000162]
   Van der Vliet D, 2013, P AM SOC TROP MED HY
   Machado AAV, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003104
   Villar LA, 2013, PEDIATR INFECT DIS J, V32, P1102, DOI 10.1097/INF.0b013e31829b8022
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Zambrano B, 2014, J PEDIATR INFECT DIS, V3, P181, DOI 10.1093/jpids/piu071
NR 31
TC 525
Z9 540
U1 3
U2 120
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 8
PY 2015
VL 372
IS 2
BP 113
EP 123
DI 10.1056/NEJMoa1411037
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AY2UA
UT WOS:000347443300006
PM 25365753
DA 2020-12-15
ER

PT J
AU de Andrade, ALDL
   Novaes, MM
   Germano, AR
   Luz, KG
   Freitas, RD
   Galvao, HC
AF Dias Leite de Andrade, Ana Luiza
   Novaes, Marcio Menezes
   Germano, Adriano Rocha
   Luz, Kleber Giovanni
   Freitas, Roseana de Almeida
   Galvao, Hebel Cavalcanti
TI Acute Primary Actinomycosis Involving the Hard Palate of a Diabetic
   Patient
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID MELLITUS
AB Actinomycosis is a relatively rare infection caused by saprophytic bacteria of the oral cavity and gastrointestinal tract that can become pathogenic. The chronic hyperglycemia of diabetes mellitus induces events that promote structural changes in various tissues and are associated with problems in wound healing. This infection remains largely unknown to most clinicians because of its different presentations, and palatal involvement is extremely rare. This report describes the case of a 46-year-old woman who was diagnosed with actinomycosis involving the hard palate. The main clinical, histopathologic, and therapeutic characteristics and differential diagnosis of actinomycosis are reviewed. To date, 3 cases of actinomycosis involving the hard palate have been reported. (C) 2014 American Association of Oral and Maxillofacial Surgeons
C1 [Dias Leite de Andrade, Ana Luiza; Novaes, Marcio Menezes; Germano, Adriano Rocha; Luz, Kleber Giovanni; Freitas, Roseana de Almeida; Galvao, Hebel Cavalcanti] Univ Fed Rio Grande do Norte, BR-59056 00 Natal, RN, Brazil.
RP de Andrade, ALDL (corresponding author), Univ Fed Rio Grande do Norte, Dept Odontol, Av Senador Salgado Filho 1787, BR-59056 00 Natal, RN, Brazil.
EM ana_luiza_dla@hotmail.com
RI Andrade, Ana Luiza/K-5665-2019; GERMANO, ADRIANO ROCHA/ABF-1550-2020
CR Ablanedo-Terrazas Y, 2012, CASE REP MED, DOI 10.1155/2012/679728
   Bastos AD, 2011, DIABETES RES CLIN PR, V92, P100, DOI 10.1016/j.diabres.2011.01.011
   Blakytny R, 2006, DIABETIC MED, V23, P594, DOI 10.1111/j.1464-5491.2006.01773.x
   Brook I, 2008, SOUTH MED J, V101, P1019, DOI 10.1097/SMJ.0b013e3181864c1f
   Carinci F, 2007, GERODONTOLOGY, V24, P121, DOI 10.1111/j.1741-2358.2007.00168.x
   Carlson DL, 2009, ARCH PATHOL LAB MED, V133, P692, DOI 10.1043/1543-2165-133.5.692
   De D, 2011, J AM ACAD DERMATOL, V65, P1235, DOI 10.1016/j.jaad.2009.02.043
   Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V
   Garcia NG, 2012, CASE REP PATHOL, DOI 10.1155/2012/679325
   Gocmen G, 2011, ORAL SURG ORAL MED O, V112, pE121, DOI 10.1016/j.tripleo.2011.06.008
   Herman WW, 1998, J ORAL MAXIL SURG, V56, P1098, DOI 10.1016/S0278-2391(98)90264-6
   Hirsch Tobias, 2008, BMC Surg, V8, P5, DOI 10.1186/1471-2482-8-5
   Iacopino A M, 1995, Oral Dis, V1, P214
   Johnson N, 2005, WHO CLASSIFICATION T, P171
   Lin HC, 2007, OPER TECH OTOLARYNGO, V18, P329
   NIELSEN PM, 1987, INT J ORAL MAX SURG, V16, P440, DOI 10.1016/S0901-5027(87)80081-4
   RUBIN MM, 1995, J ORAL MAXIL SURG, V53, P701, DOI 10.1016/0278-2391(95)90176-0
   Samant S, 2009, BRIT J ORAL MAX SURG, V47, P417, DOI 10.1016/j.bjoms.2008.10.009
   SAMUELS RHA, 1988, BRIT J ORAL MAX SURG, V26, P458, DOI 10.1016/0266-4356(88)90066-6
   Sato T, 2012, ARCH ORAL BIOL, V57, P1522, DOI 10.1016/j.archoralbio.2012.07.012
   Schubert S, 1995, IMMUN INFEKT, V23, P200
   Smego RA, 1998, CLIN INFECT DIS, V26, P1255
   WYSOCKI J, 1992, THYMUS, V20, P63
NR 23
TC 8
Z9 9
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
EI 1531-5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD MAR
PY 2014
VL 72
IS 3
BP 537
EP 541
DI 10.1016/j.joms.2013.08.006
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA AA5OZ
UT WOS:000331150800013
PM 24528563
OA Green Published
DA 2020-12-15
ER

PT J
AU Luz, KG
   de Britto, MHMF
   de Farias, DC
   Almeida, MV
   Figueiredo, NMD
   Silva, PDNE
AF Luz, Kleber Giovanni
   Marques Fonseca de Britto, Maria Helena
   de Farias, Domitila Costa
   Almeida, Mayara Varaschim
   de Sousa Figueiredo, Nastassja Morgana
   Nacacio e Silva, Paula de Medeiros
TI Mycobacterium fortuitum-related lymphadenitis associated with the
   varicella-zoster virus
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Lymphadenitis; Non-tuberculous mycobacteria; Varicella-zoster virus;
   Mycobacterium fortuitum
ID IMMUNITY
AB Lymphadenitis caused by non-tuberculous mycobacteria is an uncommon manifestation in immunocompetent individuals. Here, we report a case of Mycobacterium fortuitum infection in a previously healthy 9-year-old patient who developed cervical lymphadenitis evolving to a suppurative ulcer associated with a varicella-zoster virus infection. We discuss the relationship between the varicella-zoster virus and the immune response of the host as an explanation for the unusual progression of the case.
C1 [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Dept Infectol, BR-59072970 Natal, RN, Brazil.
   [Marques Fonseca de Britto, Maria Helena] Ctr Patol Clin, Natal, RN, Brazil.
   [de Farias, Domitila Costa; Almeida, Mayara Varaschim; de Sousa Figueiredo, Nastassja Morgana; Nacacio e Silva, Paula de Medeiros] Univ Fed Rio Grande do Norte, Curso Med, BR-59072970 Natal, RN, Brazil.
RP Luz, KG (corresponding author), Rua Des Tulio Bezerra de Melo 3631 Apt 1000, BR-5964580 Natal, RN, Brazil.
EM klebergluz@gmail.com
OI Silva, Paula/0000-0001-7717-4947
CR BELSEY MA, 1967, AM J DIS CHILD, V113, P444, DOI 10.1001/archpedi.1967.02090190090007
   Cassidy PM, 2009, CLIN INFECT DIS, V49, pE124, DOI 10.1086/648443
   Falkinham JO, 2010, FUTURE MICROBIOL, V5, P951, DOI 10.2217/FMB.10.53
   Guide SV, 2002, INFECT DIS CLIN N AM, V16, P163, DOI 10.1016/S0891-5520(03)00051-5
   Idigoras P, 2000, EUR J CLIN MICROBIOL, V19, P350, DOI 10.1007/s100960050492
   Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011
   Sen N, 2011, PNAS, V109, P600
   Stenger S, 1999, CURR OPIN MICROBIOL, V2, P89, DOI 10.1016/S1369-5274(99)80015-0
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JAN-FEB
PY 2014
VL 47
IS 1
BP 119
EP 121
DI 10.1590/0037-8682-0166-2013
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AC1UE
UT WOS:000332281200025
PM 24603748
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU da Cunha, MA
   Nery, AF
   Lima, FP
   Diniz, J
   Neto, JM
   Calado, NB
   Luz, KG
   Milan, EP
AF da Cunha, Mirella Alves
   Nery, Andreia Ferreira
   Lima, Francisco Pignataro
   Diniz Junior, Jose
   Maciel Neto, Jose
   Calado, Nicacia Barbosa
   Luz, Kleber Giovanni
   Milan, Eveline Pipolo
TI Rhinocerebral zygomycosis in a diabetic patient
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Zygomicosis; Diabetes mellitus; Tuberculosis
AB Rhinocerebral zygomycosis is the most frequent form of fungal infection caused by members of the Zygomycetes class. A fatal case of rhinocerebral zygomycosis caused by Rhizopus (oryzae) arrhizus with histopathological and mycological diagnosis is reported in a diabetic patient.
C1 [da Cunha, Mirella Alves; Nery, Andreia Ferreira; Calado, Nicacia Barbosa; Luz, Kleber Giovanni; Milan, Eveline Pipolo] Univ Fed Rio Grande do Norte, Dept Infectol, Hosp Giselda Trigueiro, BR-59072970 Natal, RN, Brazil.
   [Lima, Francisco Pignataro] Univ Fed Rio Grande do Norte, Dept Patol, BR-59072970 Natal, RN, Brazil.
   [Diniz Junior, Jose] Univ Fed Rio Grande do Norte, Dept Med Integrada, BR-59072970 Natal, RN, Brazil.
   [Maciel Neto, Jose] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, BR-59072970 Natal, RN, Brazil.
RP Milan, EP (corresponding author), Av Alm Alexandrino de Alencar 1384-500, BR-59015350 Natal, RN, Brazil.
EM evepipolo@gmail.com
CR Brown J, 2005, AM J HEALTH-SYST PH, V62, P2593, DOI 10.2146/ajhp050188
   del Palacio Amalia, 1999, Revista Iberoamericana de Micologia, V16, P50
   Islam MN, 2007, ORAL SURG ORAL MED O, V104, pE28, DOI 10.1016/j.tripleo.2007.06.014
   Lanternier F, 2009, CLIN MICROBIOL INFEC, V15, P21, DOI 10.1111/j.1469-0691.2009.02975.x
   Patel T, 2007, J MED CASE REPORTS, V17, P1
   Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000
   Romano C, 2002, MYCOSES, V45, P45, DOI 10.1046/j.1439-0507.2002.00703.x
   Sundaram C, 2005, MYCOSES, V48, P396, DOI 10.1111/j.1439-0507.2005.01167.x
   Torres-Narbona M, 2007, REV ESP QUIM, V20, P375
NR 9
TC 5
Z9 5
U1 0
U2 0
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD MAR-APR
PY 2011
VL 44
IS 2
BP 257
EP 259
DI 10.1590/S0037-86822011000200027
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 761JT
UT WOS:000290394800027
PM 21552748
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Luz, KG
   Tuon, FF
   Duarte, MIS
   Maia, GM
   Matos, P
   Ramos, AMD
   Nicodemo, AC
AF Luz, Kleber Giovanni
   Tuon, Felipe Francisco
   Duarte, Maria Irma Seixas
   Maia, Guilherme Mariz
   Matos, Paulo
   de Oliveira Ramos, Ana Maria
   Nicodemo, Antonio Carlos
TI Cytokine expression in the duodenal mucosa of patients with visceral
   leishmaniasis
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Visceral leishmaniasis; Leishmaniasis; Leishmania
ID INVOLVEMENT; INFECTION; COLITIS
AB Introduction: Visceral leishmaniasis (VL) is a neglected tropical disease with a complex immune response in different organs. This pattern of organ-specific immune response has never been evaluated in the gastrointestinal tract. The aim of this study was to determine the in situ immune response in duodenal biopsies on patients with VL. Methods: A case-control study was conducted on 13 patients with VL in comparison with nine controls. The immune response was evaluated using immunohistochemistry, for CD4, CD8, CD68, IL-4, IFN-gamma, TNF-alpha and IL-10. Histological findings from the villi, crypts and inflammatory process were analyzed. Results: All the cases of VL presented Leishmania antigens. No antigen was detected in the control group. The villus size was greater in the VL patients (p < 0.05). CD68 (macrophages) and CD4 levels were higher in the VL patients (p < 0.05). No differences in the expression of CD8, TNF-alpha, IL-10 or IL-4 were demonstrated. The number of cells expressing IFN-gamma was lower in the VL patients (p < 0.05). Conclusions: Low levels of cytokines were found in the gastrointestinal tract of patients with VL. This pattern was not found in other organs affected by the disease. Immunotolerance of this tissue against Leishmania could explain these findings, as occurs with intestinal bacteria.
C1 [Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Dept Infect Dis, BR-59072970 Natal, RN, Brazil.
   [Tuon, Felipe Francisco; Nicodemo, Antonio Carlos] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05508 Sao Paulo, Brazil.
   [Duarte, Maria Irma Seixas] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Infect Dis Pathol, BR-05508 Sao Paulo, Brazil.
   [Maia, Guilherme Mariz] Hosp Infantil Varela Santiago, Natal, RN, Brazil.
   [Matos, Paulo] Med Lab Pathol Getulio Sales, Natal, RN, Brazil.
   [de Oliveira Ramos, Ana Maria] Univ Fed Rio Grande do Norte, Hosp Pediat, BR-59072970 Natal, RN, Brazil.
RP Luz, KG (corresponding author), R Desembargador Tulio Bezerra de Melo 3631-1000, BR-59065200 Natal, RN, Brazil.
EM luz@ufrnet.br
RI Tuon, Felipe/F-4034-2012
OI Tuon, Felipe/0000-0003-3471-1786
CR Adamama-Moraitou KK, 2007, AM J TROP MED HYG, V76, P53, DOI 10.4269/ajtmh.2007.76.53
   Baba Chalamalasetty Sreenivasa, 2006, Indian J Gastroenterol, V25, P309
   Barati M, 2008, ANN TROP MED PARASIT, V102, P635, DOI 10.1179/136485908X311858
   DUARTE MIS, 1987, REV INST MED TROP SP, V29, P131, DOI 10.1590/S0036-46651987000300003
   GONZALEZ JL, 1986, BRIT J EXP PATHOL, V67, P353
   Guedes F, 2008, BRIT J DERMATOL, V159, P839, DOI 10.1111/j.1365-2133.2008.08755.x
   Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X
   Iweala OI, 2006, IMMUNOL REV, V213, P82, DOI 10.1111/j.1600-065X.2006.00431.x
   Moussallem TM, 2007, HUM PATHOL, V38, P1239, DOI 10.1016/j.humpath.2007.01.015
   MUIGAI R, 1983, LANCET, V27, P476
   Tuon FF, 2009, PARASITE IMMUNOL, V31, P98, DOI 10.1111/j.1365-3024.2008.01080.x
   Xu DM, 2003, J IMMUNOL, V170, P394, DOI 10.4049/jimmunol.170.1.394
NR 12
TC 3
Z9 3
U1 0
U2 3
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JUL-AUG
PY 2010
VL 43
IS 4
BP 393
EP 395
DI 10.1590/S0037-86822010000400011
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 645BO
UT WOS:000281426100011
PM 20802937
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Souza, RM
   de Oliveira, IBMD
   Paiva, VCD
   Lima, KC
   dos Santos, RP
   de Almeida, JB
   Luz, KG
AF Souza, Roberto Mascarenhas
   Maia Delfino de Oliveira, Isaac Braullio
   de Sousa Paiva, Vinicius Camara
   Lima, Kenio Costa
   dos Santos, Rivaldo Pereira
   de Almeida, Jose Bruno
   Luz, Kleber Giovanni
TI Presence of antibodies against Leishmania chagasi in haemodialysed
   patients
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Visceral leishmaniasis; Leishmania chagasi; Haemodialysis; Kidney
   transplant; Asymptomatic infection; IFAT
ID VISCERAL LEISHMANIASIS
AB In the last decades there has been an increase in cases of viscera[ leishmaniasis complicating the post-transplant phase, mainly following kidney transplantation. The aim of this study was to evaluate the reactivity of haemodialysed patients using IFAT. Blood samples of 310 individuals from Natal, RN, Brazil, were collected and analysed. Data regarding blood transfusion, cause of end-stage renal disease and duration of haemodialysis were also analysed. In total, 69 patients (22.3%) were positive by IFAT. This study suggests that antibody detection should be performed in this group of patients since they are possible candidates for kidney transplantation. (C) 2009 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 [Souza, Roberto Mascarenhas; Maia Delfino de Oliveira, Isaac Braullio; de Sousa Paiva, Vinicius Camara; Luz, Kleber Giovanni] Univ Fed Rio Grande do Norte, Dept Infect Dis, Natal, RN, Brazil.
   [Lima, Kenio Costa] Univ Fed Rio Grande do Norte, Postgrad Program Hlth Sci & Dent, Natal, RN, Brazil.
   [dos Santos, Rivaldo Pereira; de Almeida, Jose Bruno] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Natal, RN, Brazil.
RP Luz, KG (corresponding author), Hosp Giselda Trigueiro, Dept Infectol, Rua Conego Monte SN, BR-59064500 Natal, RN, Brazil.
EM klebergluz@gmail.com
OI Lima, Kenio Costa/0000-0002-5668-4398
CR Basset D, 2005, MICROBES INFECT, V7, P1370, DOI 10.1016/j.micinf.2005.06.002
   Elshafie AI, 2006, AM J TROP MED HYG, V75, P864, DOI 10.4269/ajtmh.2006.75.864
   Luz KG, 1997, AM J TROP MED HYG, V57, P168, DOI 10.4269/ajtmh.1997.57.168
   Pesanti EL, 2001, INFECT DIS CLIN N AM, V15, P813, DOI 10.1016/S0891-5520(05)70174-4
   Pisoni RL, 2004, AM J KIDNEY DIS, V44, P94, DOI 10.1053/j.ajkd.2004.03.023
NR 5
TC 7
Z9 7
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL
PY 2009
VL 103
IS 7
BP 749
EP 751
DI 10.1016/j.trstmh.2009.01.003
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 465TQ
UT WOS:000267610900020
PM 19237180
OA Green Published
DA 2020-12-15
ER

PT J
AU Borj-Cabrera, GP
   Pontes, NNC
   da Silva, VO
   de Souza, EP
   Santos, WR
   Gomes, EM
   Luz, KG
   Palatnik, M
   de Sousa, CBP
AF Borj-Cabrera, GP
   Pontes, NNC
   da Silva, VO
   de Souza, EP
   Santos, WR
   Gomes, EM
   Luz, KG
   Palatnik, M
   de Sousa, CBP
TI Long lasting protection against canine kala-azar using the FML-QuilA
   saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante,
   RN)
SO VACCINE
LA English
DT Article
DE canine visceral leishmaniasis; phase III trial; zoonoses; kala-azar;
   Leishmania donovani
ID FUCOSE-MANNOSE LIGAND; HUMAN VISCERAL LEISHMANIASIS; IMMUNE-RESPONSES;
   DONOVANI; INFECTION; DISEASE; ANTIBODIES; PROGNOSIS; DIAGNOSIS; ANTIGENS
AB Naturally exposed dogs of an endemic area were vaccinated with the fucose mannose ligand (FML) antigen of Leishmania donovani in formulation with QuilA saponin. The 100% of vaccinees were seropositive to FML and showed intradermal reaction to L. donovani lysate, 2 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls along a 3.5 years period (ANOVA, P < 0.0001). The 25% of the control animals (two dogs on the first year and six dogs on the fourth year, respectively) and 5% of the vaccinees (one dog during the fourth year) developed clinical and fatal disease until the end of experiment. This difference was significant (chi(2) = 3.93, P < 0.05). This means that 95% protection against kala-azar was achieved in vaccinees, after FML-QuilA vaccination (80% of vaccine efficacy (VE)). Leishmania infection was also confirmed, 3.5 years after vaccination, in saline controls that showed positive polymerase chain reaction (PCR) for Leishmania DNA and FML-serology with no intradermal reaction. Higher seropositivities and intradermal reactions with no Leishmanial DNA were detected in vaccinees. The FML-QuilA vaccine induced a significant, long lasting and strong protective effect against canine kala-azar in the field. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Fed Rio de Janeiro, CCS, Inst Microbiol Prof Paulo De Goes, BR-21941590 Rio De Janeiro, RJ, Brazil.
   Univ Fed Rio Grande do Norte, Fac Med, BR-59072970 Natal, RN, Brazil.
   Univ Fed Rio de Janeiro, Hosp Clementino Fraga Filho, Fac Med, BR-21941590 Rio De Janeiro, RJ, Brazil.
RP de Sousa, CBP (corresponding author), Univ Fed Rio de Janeiro, CCS, Inst Microbiol Prof Paulo De Goes, Cidade Univ,Ilha Fundao,Caixa Postal 68040, BR-21941590 Rio De Janeiro, RJ, Brazil.
EM immgcpa@micro.ufrj.br
OI Borja-Cabrera, Gulnara Patricia/0000-0002-6996-6896; Palatnik-de-Sousa,
   Clarisa B./0000-0002-6231-0608
CR ANTUNES CM, 1986, INT J EPIDEMIOL, V15, P572, DOI 10.1093/ije/15.4.572
   Ashford DA, 1998, AM J TROP MED HYG, V59, P53, DOI 10.4269/ajtmh.1998.59.53
   BOMFORD R, 1992, AIDS RES HUM RETROV, V8, P1765, DOI 10.1089/aid.1992.8.1765
   Cabrera GPB, 1999, AM J TROP MED HYG, V61, P296, DOI 10.4269/ajtmh.1999.61.296
   CABRERA GPB, 2000, THESIS FEDERAL FLUMI
   Cardoso L, 1998, VET PARASITOL, V79, P213, DOI 10.1016/S0304-4017(98)00169-1
   CHANG YF, 1995, INFECT IMMUN, V63, P3543, DOI 10.1128/IAI.63.9.3543-3549.1995
   Cox SJ, 1999, VACCINE, V17, P1858, DOI 10.1016/S0264-410X(98)00486-1
   da Silva VO, 2000, VACCINE, V19, P1082, DOI 10.1016/S0264-410X(00)00339-X
   De Luca PM, 2001, ACTA TROP, V80, P251, DOI 10.1016/S0001-706X(01)00181-4
   DEPLAZES P, 1995, PARASITE IMMUNOL, V17, P451, DOI 10.1111/j.1365-3024.1995.tb00914.x
   DESOUSA CBP, 1994, CIENCIA CULTURA, V46, P290
   DUNAN S, 1989, PARASITE IMMUNOL, V11, P397, DOI 10.1111/j.1365-3024.1989.tb00676.x
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   FLIES JL, 1973, STAT METHODS RATES P, P190
   GENARO O, 1992, MEM I OSWALDO CRUZ, V87, P163, DOI 10.1590/S0074-02761992000100025
   GENARO O, 1996, MEM I O CRUZ MEMIOC, V91, P166
   Guarga JL, 2000, RES VET SCI, V69, P249, DOI 10.1053/rvsc.2000.0419
   Khalil EAG, 2000, LANCET, V356, P1565, DOI 10.1016/S0140-6736(00)03128-7
   Lasri S, 1999, VET RES, V30, P441
   Mayrink W, 1996, MEM I OSWALDO CRUZ, V91, P695, DOI 10.1590/S0074-02761996000600006
   MENDES AC, 2001, P 5 M APPL RES LEISH, P80
   Nieto CG, 1999, VET IMMUNOL IMMUNOP, V67, P117, DOI 10.1016/S0165-2427(98)00213-X
   PALATNIK CB, 1989, INFECT IMMUN, V57, P754, DOI 10.1128/IAI.57.3.754-763.1989
   Palatnik-de-Sousa CB, 2001, AM J TROP MED HYG, V65, P510, DOI 10.4269/ajtmh.2001.65.510
   PALATNIKDESOUSA CB, 1995, T ROY SOC TROP MED H, V89, P390, DOI 10.1016/0035-9203(95)90022-5
   PALATNIKDESOUSA CB, 1993, ACTA TROP, V53, P59, DOI 10.1016/0001-706X(93)90006-W
   PALATNIKDESOUSA CB, 1994, BRAZ J MED BIOL RES, V27, P547
   ParanhosSilva M, 1996, AM J TROP MED HYG, V55, P39, DOI 10.4269/ajtmh.1996.55.39
   PINELLI E, 1994, INFECT IMMUN, V62, P229, DOI 10.1128/IAI.62.1.229-235.1994
   RIKIHISA Y, 1991, VET MICROBIOL, V27, P339, DOI 10.1016/0378-1135(91)90159-D
   Santos WR, 1999, VACCINE, V17, P2554, DOI 10.1016/S0264-410X(99)00058-4
   SCHETTERS TPM, 1992, PARASITE IMMUNOL, V14, P295, DOI 10.1111/j.1365-3024.1992.tb00469.x
   Sjolander S, 1996, VACCINE, V14, P344, DOI 10.1016/0264-410X(95)00163-U
   Solano-Gallego L, 2000, VET PARASITOL, V90, P37, DOI 10.1016/S0304-4017(00)00223-5
   TESH RB, 1995, AM J TROP MED HYG, V52, P287, DOI 10.4269/ajtmh.1995.52.287
   *WHO, 1997, WHOTDRMALVAC97, P24
NR 37
TC 145
Z9 148
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2002
VL 20
IS 27-28
BP 3277
EP 3284
AR PII S0264-410X(02)00294-3
DI 10.1016/S0264-410X(02)00294-3
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 602CB
UT WOS:000178486700007
PM 12213397
DA 2020-12-15
ER

PT J
AU Ramos, AMO
   Gayotto, LCC
   Clemente, CM
   Mello, ES
   Luz, KG
   Freitas, ML
AF Ramos, AMO
   Gayotto, LCC
   Clemente, CM
   Mello, ES
   Luz, KG
   Freitas, ML
TI Reversible vanishing bile duct syndrome induced by carbamazepine
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE hepatotoxic drugs; carbamazepine; vanishing bile duct syndrome;
   ductopenia
ID HEPATITIS
AB Carbamazepine, a widely used anticonvulsant, can induce hepatotoxicity, usually evolving with an acute hepatitis that ceases after drug withdrawal. Carbamazepine-induced vanishing bile duct syndrome (VBDS) is a rare complication and has seldom been reported in the medical literature. This report presents a case of a 26-year-old male who had onset of epilepsy at 12 months of age and was initially treated with phenobarbital. Carbamazepine (11200 mg/day) was added in June 1996 when he was 22 years old to control the frequency of seizures. Two years later, during a routine investigation, elevation of serum gamma-glutamyltransferase (GGT) levels was detected. For this reason, the patient was weaned off carbamazepine, followed 6 months later by complete withdrawal of the drug. The first liver biopsy disclosed total absence of interlobular bile ducts (IBD) in 30 portal tracts. Fourteen months later, a control biopsy showed the presence of IBD in eight of 14 portal tracts. There was also a decrease of GGT levels detected 27 months after withdrawal of carbamazepine. This case illustrates the ductopenic effect of carbamazepine when used for a prolonged time, as reported in three previous publications. However, this is the first case in which there was a remission of the VBDS and bile duct regeneration after withdrawal of the drug. (C) 2002 Lippincott Williams Wilkins.
C1 Lab Med Patol Getulio Oliveira Sales, Natal, RN, Brazil.
   Univ Sao Paulo, Hosp Clin, Div Anat Patol, Sao Paulo, Brazil.
   Univ Fed Rio Grande Norte, Dept Doencas Infecciosas & Trop, BR-59072970 Natal, RN, Brazil.
RP Ramos, AMO (corresponding author), Rua Alameda Margaridas 1255,Apto 400, BR-59020580 Natal, RN, Brazil.
CR DEGGOT C, 1992, HEPATOLOGY, V15, P244
   Desmet V. J., 1997, Journal of Hepatology, V26, P31, DOI 10.1016/S0168-8278(97)82330-6
   DINCSOY HP, 1982, GASTROENTEROLOGY, V83, P694
   FORBES GM, 1992, GASTROENTEROLOGY, V102, P1385
   GALOSCY C, 1994, J CLIN GASTROENTEROL, V19, P269
   LEVY M, 1981, ANN INTERN MED, V95, P64, DOI 10.7326/0003-4819-95-1-64
   LUDWIG J, 1988, J HEPATOL, V7, P193, DOI 10.1016/S0168-8278(88)80482-3
   MANUVEL JC, 1987, GASTROENTEROLOGY, V93, P245
   OZDEMIR S, 2001, TURK J GASTROENTEROL, V12, P233
   PELLOCK JM, 1987, EPILEPSIA S3, V28, P64
   SHERLOCK S, 1987, LANCET, V2, P493
   SOFFER EE, 1983, SOUTHERN MED J, V76, P681, DOI 10.1097/00007611-198305000-00043
   TURNER IB, 1989, MED J AUSTRALIA, V151, P701, DOI 10.5694/j.1326-5377.1989.tb139652.x
   WILLIAMS SJ, 1986, J GASTROEN HEPATOL, V1, P159, DOI 10.1111/j.1440-1746.1986.tb00110.x
   1989, LANCET, V2, P595
NR 15
TC 18
Z9 19
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0954-691X
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD SEP
PY 2002
VL 14
IS 9
BP 1019
EP 1022
DI 10.1097/00042737-200209000-00014
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 594JK
UT WOS:000178046200014
PM 12352223
DA 2020-12-15
ER

PT J
AU da Silva, VO
   Borja-Cabrera, GP
   Pontes, NNC
   de Souza, EP
   Luz, KG
   Palatnik, M
   de Sousa, CBP
AF da Silva, VO
   Borja-Cabrera, GP
   Pontes, NNC
   de Souza, EP
   Luz, KG
   Palatnik, M
   de Sousa, CBP
TI A phase III trial of efficacy of the FML-vaccine against canine
   kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN)
SO VACCINE
LA English
DT Article
DE canine visceral leishmaniasis; zoonoses; kala-azar; Leishmania donovani
ID FUCOSE-MANNOSE LIGAND; EXPERIMENTAL VISCERAL LEISHMANIASIS; PROMASTIGOTE
   INTERNALIZATION; DONOVANI; ANTIGEN; COMPONENT; INFANTUM; PROTEIN; MICE;
   DNA
AB Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vaccinated with the fucose mannose ligand (FML)-vaccine of Leishmania donovani. A total of 97% of vaccinees were seropositive to FML and 100% showed intradermal reaction to L. donovani lysate, 7 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls (ANOVA, P < 0.0001). After 2 years, 92% (<chi>(2) = 6.996; P < 0.0025) protection was achieved: only 8% of vaccinees showed mild signs of kala-azar with no deaths while 33% of controls developed clinical or fatal disease. The FML-vaccine induced a significant, long-lasting and strong protective effect against canine kala-azar in the field. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Univ Fed Rio de Janeiro, CCS, Inst Microbiol, Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio Grande do Norte, Fac Med, BR-59072970 Natal, RN, Brazil.
   Hosp Univ Clementino Fraga Filho, Fac Med, Rio De Janeiro, Brazil.
RP de Sousa, CBP (corresponding author), Univ Fed Rio de Janeiro, CCS, Inst Microbiol, Ilha Fundao, Cidade Univ,CP 68040, BR-21941590 Rio De Janeiro, Brazil.
EM immgcpa@microbio.ufrj.br
OI Palatnik-de-Sousa, Clarisa B./0000-0002-6231-0608; Borja-Cabrera,
   Gulnara Patricia/0000-0002-6996-6896
CR ABRANCHES P, 1991, PARASITE IMMUNOL, V13, P537, DOI 10.1111/j.1365-3024.1991.tb00550.x
   ABRANCHES P, 1991, J PARASITOL, V77, P557, DOI 10.2307/3283159
   ALVAR J, 1994, ANN TROP MED PARASIT, V88, P371, DOI 10.1080/00034983.1994.11812879
   ANTUNES CM, 1986, INT J EPIDEMIOL, V15, P572, DOI 10.1093/ije/15.4.572
   BINHAZIM AA, 1993, AM J VET RES, V54, P113
   BORJACABRERA GP, 1998, 25 ANN M BAS RES CHA, V93, P288
   Cabrera GPB, 1999, AM J TROP MED HYG, V61, P296, DOI 10.4269/ajtmh.1999.61.296
   COSTA RT, 1996, MEM I OSW CRUZ MEMIO, V91, P154
   DUNAN S, 1989, PARASITE IMMUNOL, V11, P397, DOI 10.1111/j.1365-3024.1989.tb00676.x
   EVANS TG, 1990, AM J TROP MED HYG, V42, P118, DOI 10.4269/ajtmh.1990.42.118
   FLIES JL, 1973, STAT METHODS RATES P, P190
   GENARO O, 1992, MEM I OSWALDO CRUZ, V87, P163, DOI 10.1590/S0074-02761992000100025
   Gomes E. M., 1994, J BRAZ ASS ADV SCI, V46, P290
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   Handman E, 1997, PARASITOL TODAY, V13, P236, DOI 10.1016/S0169-4758(97)01060-0
   JAFFE CL, 1990, J IMMUNOL, V144, P699
   JARDIM A, 1991, J IMMUNOL, V147, P3538
   MOLINA R, 1994, T ROY SOC TROP MED H, V88, P491, DOI 10.1016/0035-9203(94)90446-4
   NASCIMENTO MDSB, 1993, T ROY SOC TROP MED H, V87, P91, DOI 10.1016/0035-9203(93)90439-W
   OLIVEIRA GGS, 1993, MEM I OSWALDO CRUZ, V88, P243, DOI 10.1590/S0074-02761993000200011
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   Otero ACS, 2000, AM J TROP MED HYG, V62, P128, DOI 10.4269/ajtmh.2000.62.128
   PALATNIK CB, 1990, PARASITOL RES, V76, P289, DOI 10.1007/BF00928181
   PALATNIK CB, 1989, INFECT IMMUN, V57, P754, DOI 10.1128/IAI.57.3.754-763.1989
   Palatnik-de-Sousa Clarisa B., 1996, Revista da Sociedade Brasileira de Medicina Tropical, V29, P153
   PALATNIKDESOUSA CB, 1995, T ROY SOC TROP MED H, V89, P390, DOI 10.1016/0035-9203(95)90022-5
   PALATNIKDESOUSA CB, 1993, ACTA TROP, V53, P59, DOI 10.1016/0001-706X(93)90006-W
   PALATNIKDESOUSA CB, 1994, BRAZ J MED BIOL RES, V27, P547
   ParanhosSilva M, 1996, AM J TROP MED HYG, V55, P39, DOI 10.4269/ajtmh.1996.55.39
   PINELLI E, 1994, INFECT IMMUN, V62, P229, DOI 10.1128/IAI.62.1.229-235.1994
   Santos WR, 1997, VACCINE, V15, P1024, DOI 10.1016/S0264-410X(96)00292-7
   Santos WR, 1999, VACCINE, V17, P2554, DOI 10.1016/S0264-410X(99)00058-4
   Skeiky YAW, 1998, J IMMUNOL, V161, P6171
   TESH RB, 1995, AM J TROP MED HYG, V52, P287, DOI 10.4269/ajtmh.1995.52.287
   *WORLD HLTH ORG, 1997, TROP DIS RES PROGR 1, P1
NR 35
TC 93
Z9 96
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 8
PY 2000
VL 19
IS 9-10
BP 1082
EP 1092
DI 10.1016/S0264-410X(00)00339-X
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 383QW
UT WOS:000165894700014
PM 11137242
DA 2020-12-15
ER

PT J
AU Otero, ACS
   da Silva, VO
   Luz, KG
   Palatnik, M
   Pirmez, C
   Fernandes, O
   de Sousa, CBP
AF Otero, ACS
   da Silva, VO
   Luz, KG
   Palatnik, M
   Pirmez, C
   Fernandes, O
   de Sousa, CBP
TI Short report: Occurrence of Leishmania donovani DNA in donated blood
   from seroreactive Brazilian blood donors
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID FUCOSE-MANNOSE LIGAND; VISCERAL LEISHMANIASIS; PROMASTIGOTE
   INTERNALIZATION; GLYCOCONJUGATE LIGANDS; MURINE MACROPHAGES; KALA-AZAR
AB Human visceral leishmaniasis (kala-azar) transmitted by blood transfusion has been described in previous reports. Seroprevalence of antibodies to Leishmania donovani was shown to be related to prior blood transfusions in multiply transfused hemodialysis patients in Natal. Rio Grande do Norte, Brazil. In this study, a possible correlation between seroreactivity and the presence of L. donovani DNA was investigated in asymptomatic healthy blood donors. Sera were tested using the fucose mannose ligand (FML) ELISA, which was shown to have ii sensitivity of 100%, a specificity of 96-100%. reliability, and diagnostic and prognostic potential for the detection of human and canine kala-azar. respectively. Leishmanial DNA was assessed by the polymerase chain reaction (PCR) and dot-blot hybridization techniques in blood and bone: marrow samples. Among 21 FML-seroreactive asymptomatic blood donors, 5 (24%) were positive by the PCR and 9 (4.3%) were positive in it dot-blot assay of blood samples. showing a significant correlation (chi(2) = 14.24, P < 0.01). No Leishmania DNA was detected in 20 FMF non-reactive blood donors. Our results point to the need for control of transmission of kala-azar by blood transfusion in nl ens endemic for this disease.
C1 UFRJ, CCS, Inst Microbiol Professor Paulo de Goes, Dept Microbiol Geral, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio Grande Norte, Fac Med, BR-59037170 Natal, RN, Brazil.
   UFRJ, Fac Med, Univ Hosp, BR-21941590 Rio De Janeiro, Brazil.
   Fdn Oswaldo Cruz, Dept Bioquim & Biol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Estadual Rio de Janeiro, Dept Parasitol, BR-20550013 Rio De Janeiro, Brazil.
RP de Sousa, CBP (corresponding author), UFRJ, CCS, Inst Microbiol Professor Paulo de Goes, Dept Microbiol Geral, Caixa Postal 68040,Cidade Univ,Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
RI Pirmez, Claude/AAF-9977-2019; Pirmez, Claude/K-8579-2012
OI Pirmez, Claude/0000-0002-7443-0455; Pirmez, Claude/0000-0002-7443-0455;
   Palatnik-de-Sousa, Clarisa B./0000-0002-6231-0608
CR ANDRE R, 1958, TROP DIS B, V55, P379
   ASHFORD DA, 1995, AM J TROP MED HYG, V53, P251, DOI 10.4269/ajtmh.1995.53.251
   COHEN C, 1991, LANCET, V338, P128, DOI 10.1016/0140-6736(91)90129-D
   CUMMINS D, 1995, ARCH DIS CHILD, V72, P235, DOI 10.1136/adc.72.3.235
   ELTOUM IA, 1992, AM J TROP MED HYG, V46, P57, DOI 10.4269/ajtmh.1992.46.57
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9
   LOPES UG, 1986, MOL BIOCHEM PARASIT, V20, P77, DOI 10.1016/0166-6851(86)90144-1
   Luz KG, 1997, AM J TROP MED HYG, V57, P168, DOI 10.4269/ajtmh.1997.57.168
   MAUNY I, 1993, PEDIATRIE, V48, P237
   PALATNIK CB, 1990, PARASITOL RES, V76, P289, DOI 10.1007/BF00928181
   PALATNIK CB, 1989, INFECT IMMUN, V57, P754, DOI 10.1128/IAI.57.3.754-763.1989
   PALATNIKDESOUSA CB, 1995, T ROY SOC TROP MED H, V89, P390, DOI 10.1016/0035-9203(95)90022-5
   PALATNIKDESOUSA CB, 1993, ACTA TROP, V53, P59, DOI 10.1016/0001-706X(93)90006-W
   Pirmez C, 1999, J CLIN MICROBIOL, V37, P1819, DOI 10.1128/JCM.37.6.1819-1823.1999
   SCHULMAN IA, 1994, ARCH PATHOL LAB MED, V118, P366
   Singh S, 1996, TRANSFUSION, V36, P848, DOI 10.1046/j.1537-2995.1996.36996420769.x
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 18
TC 50
Z9 54
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JAN
PY 2000
VL 62
IS 1
BP 128
EP 131
DI 10.4269/ajtmh.2000.62.128
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 298NF
UT WOS:000086145500024
PM 10761737
OA Bronze
DA 2020-12-15
ER

PT J
AU Luz, KG
   DaSilva, VO
   Gomes, EM
   Machado, FCS
   Araujo, MAF
   Fonseca, HEM
   Freire, TC
   DAlmeida, JB
   Palatnik, M
   PalatnikdeSousa, CB
AF Luz, KG
   DaSilva, VO
   Gomes, EM
   Machado, FCS
   Araujo, MAF
   Fonseca, HEM
   Freire, TC
   DAlmeida, JB
   Palatnik, M
   PalatnikdeSousa, CB
TI Prevalence of anti-Leishmania donovani antibody among Brazilian blood
   donors and multiply transfused hemodialysis patients
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID FUCOSE-MANNOSE LIGAND; VISCERAL LEISHMANIASIS; PROMASTIGOTE
   INTERNALIZATION; GLYCOCONJUGATE LIGANDS; MURINE MACROPHAGES
AB The prevalence of anti-leishmania donovani antibodies was investigated in 1,500 Brazilian blood donors and multiply transfused hemodialysis patients. Sera were tested using the fucose-mannose ligand (FML) ELISA, which was shown to have 100% sensitivity and 96% specificity for kala-azar. Among 1,194 volunteer blood donors, seroreactivity was 9%, increasing to 25% in a periurban kala-azar focus. However, higher positivity (37%) was found in multiply transfused hemodialysis patients from Natal, where kala-azar is constantly present in low numbers (endemic), with sporadic outbreaks in localized regions (endemic and epidemic). Risk factors included blood transfusion, which was significantly associated with the presence of anti-leishmania antibodies (chi(2) = 8.567, P < 0.005), but did not include potential exposure to sandfly bites (chi(2) = 0.033, P > 0.1). The prevalence significantly decreased to 7% in hemodialysis patients from Rio de Janeiro, where kala-azar is only occasionally seen, and was 0% in patients undergoing continuous ambulatorial peritoneal dialysis. The prospective analysis of 27 FML-seroreactive donors from Natal revealed amastigotes of Leishmania in the bone marrow of one subject while four had clinical complaints, including splenomegaly and hepatosplenomegaly. Our results point to the need for control of blood transfusion as a possible route for transmission of kala-azar in endemic areas.
C1 FED UNIV RIO DE JANEIRO,INST MICROBIOL,BR-21944590 RIO JANEIRO,BRAZIL.
   FED UNIV RIO DE JANEIRO,UNIV HOSP,SCH MED,RIO JANEIRO,BRAZIL.
   HEMOVIDA BLOOD BANK,BR-59000000 NATAL,RN,BRAZIL.
   HEMONORTE BLOOD BANK,BR-59000000 NATAL,RN,BRAZIL.
   FED UNIV RIO DE JANEIRO,SCH MED,RIO JANEIRO,BRAZIL.
OI Palatnik-de-Sousa, Clarisa B./0000-0002-6231-0608
CR ANDRE R, 1958, TROP DIS B, V55, P379
   AYOOLA EA, 1991, J MED VIROL, V35, P155, DOI 10.1002/jmv.1890350303
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   COHEN C, 1991, LANCET, V338, P128, DOI 10.1016/0140-6736(91)90129-D
   CUMMINS D, 1995, ARCH DIS CHILD, V72, P235, DOI 10.1136/adc.72.3.235
   GROGL M, 1993, AM J TROP MED HYG, V49, P308, DOI 10.4269/ajtmh.1993.49.308
   MAUNY I, 1993, PEDIATRIE, V48, P237
   Modabber F, 1993, TROPICAL DIS RES PRO, P77
   PALATNIK CB, 1990, PARASITOL RES, V76, P289, DOI 10.1007/BF00928181
   PALATNIK CB, 1989, INFECT IMMUN, V57, P754, DOI 10.1128/IAI.57.3.754-763.1989
   Palatnik-de-Sousa Clarisa B., 1996, Revista da Sociedade Brasileira de Medicina Tropical, V29, P153
   PALATNIKDESOUSA CB, 1995, T ROY SOC TROP MED H, V89, P390, DOI 10.1016/0035-9203(95)90022-5
   PALATNIKDESOUSA CB, 1993, ACTA TROP, V53, P59, DOI 10.1016/0001-706X(93)90006-W
   PalatnikdeSousa CB, 1996, BRAZ J MED BIOL RES, V29, P1311
   PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P447, DOI 10.1016/0035-9203(74)90067-4
   SCHULMAN IA, 1994, ARCH PATHOL LAB MED, V118, P366
NR 16
TC 51
Z9 54
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD AUG
PY 1997
VL 57
IS 2
BP 168
EP 171
DI 10.4269/ajtmh.1997.57.168
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA XT635
UT WOS:A1997XT63500010
PM 9288810
DA 2020-12-15
ER

PT J
AU daSilva, VO
   Gomes, EM
   Machado, FCS
   Otero, ACS
   Luz, KG
   Pirmez, C
   Fernandes, O
   deSousa, CBP
AF daSilva, VO
   Gomes, EM
   Machado, FCS
   Otero, ACS
   Luz, KG
   Pirmez, C
   Fernandes, O
   deSousa, CBP
TI Transmission of Kala-azar transmission by blood transfusion in endemic
   areas.
SO TRANSFUSION
LA English
DT Meeting Abstract
C1 UNIV FED RIO GRANDE NORTE,BR-59072970 NATAL,RN,BRAZIL.
   FED UNIV RIO DE JANEIRO,BR-21941 RIO JANEIRO,BRAZIL.
   UNIV EST RIO DE JANEIRO,RIO JANEIRO,BRAZIL.
RI Pirmez, Claude/K-8579-2012; Pirmez, Claude/AAF-9977-2019
OI Pirmez, Claude/0000-0002-7443-0455; Pirmez, Claude/0000-0002-7443-0455
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 1996
VL 36
IS 9
SU S
BP S132
EP S132
PG 1
WC Hematology
SC Hematology
GA VK089
UT WOS:A1996VK08900132
DA 2020-12-15
ER

PT J
AU PALATNIKDESOUSA, CB
   GOMES, EM
   PARAGUAIDESOUZA, E
   PALATNIK, M
   LUZ, K
   BOROJEVIC, R
AF PALATNIKDESOUSA, CB
   GOMES, EM
   PARAGUAIDESOUZA, E
   PALATNIK, M
   LUZ, K
   BOROJEVIC, R
TI LEISHMANIA-DONOVANI - TITRATION OF ANTIBODIES TO THE FUCOSE-MANNOSE
   LIGAND AS AN AID IN DIAGNOSIS AND PROGNOSIS OF VISCERAL LEISHMANIASIS
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE LEISHMANIASIS; LEISHMANIA DONOVANI; FUCOSE-MANNOSE LIGAND; DIAGNOSIS;
   PROGNOSIS
ID LINKED-IMMUNOSORBENT-ASSAY; DIRECT AGGLUTINATION-TEST; PROMASTIGOTE
   INTERNALIZATION; GLYCOCONJUGATE LIGANDS; MURINE MACROPHAGES;
   IDENTIFICATION; SPECIFICITY; PROTEINS; ANTIGEN; AFRICAN
AB The fucose-mannose ligand (FML) is a complex glycoprotein fraction present on promastigotes and amastigotes of Leishmania donovani. It participates in parasite interaction with host macrophages in a species-specific pattern. We have tested its use in immunodiagnosis of visceral leishmaniasis (VL) in a recent outbreak in Rio Grande do Norte, north-east Brazil. Enzyme-linked immunosorbent assay (ELISA) of low concentrations of FML in 462 sera showed 100% sensitivity and 96% specificity. The FML-ELISA identified patients with overt VL (P < 0.001 compared to normal sera). It could also identify inhabitants of the endemic area who had incipient or subclinical infection with potentially severe clinical disease: more than 20% of apparently healthy subjects with a positive ELISA for FML developed overt VL during the following 10 months. FML-ELISA reactivity decreased in all patients during treatment, and became negative after parasitological cure. No cross-reaction was observed in patients infected with other Leishmania species, nor in those with Chagas disease. Determination of antibody response to FML may be useful in diagnosis of VL and in identifying patients without overt disease but with a high risk of developing severe VL.
C1 UNIV FED RIO DE JANEIRO,INST QUIM,DEPT BIOQUIM,BR-21941590 RIO JANEIRO,BRAZIL.
   UNIV FED RIO DE JANEIRO,INST MICROBIOL,DEPT MICROBIOL GERAL,BR-21941590 RIO JANEIRO,BRAZIL.
   UNIV FED RIO DE JANEIRO,FAC MED,BR-21941590 RIO JANEIRO,BRAZIL.
   UNIV FED RIO DE JANEIRO,HOSP CLEMENTINO FRAGA FILHO,BR-21941590 RIO JANEIRO,BRAZIL.
   UNIV FED RIO GRANDE NORTE,DEPT INFECTOL,NATAL,BRAZIL.
RI Borojevic, Radovan/V-8500-2019
OI Borojevic, Radovan/0000-0002-2393-7280; Palatnik-de-Sousa, Clarisa
   B./0000-0002-6231-0608
CR ALTUKHI MH, 1993, T ROY SOC TROP MED H, V87, P36, DOI 10.1016/0035-9203(93)90412-J
   ASHFORD DA, 1993, AM J TROP MED HYG, V48, P1
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BADARO R, 1986, J INFECT DIS, V156, P1003
   BOROWY NK, 1991, J INFECT DIS, V164, P422, DOI 10.1093/infdis/164.2.422
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   DUNSDORF I, 1967, TECHNIQUES BLOOD GRO, P30
   ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8
   ETGES R, 1992, ACTA TROP, V50, P205, DOI 10.1016/0001-706X(92)90077-B
   JACOBSON RL, 1986, ANN TROP MED PARASIT, V76, P45
   JAFFE CL, 1990, J IMMUNOL, V144, P699
   JAFFE CL, 1988, J INFECT DIS, V157, P1212, DOI 10.1093/infdis/157.6.1212
   MEBRAHTU YB, 1993, AM J TROP MED HYG, V48, P530, DOI 10.4269/ajtmh.1993.48.530
   MENGISTU G, 1990, T ROY SOC TROP MED H, V84, P359, DOI 10.1016/0035-9203(90)90317-8
   PALATNIK CB, 1990, PARASITOL RES, V76, P289, DOI 10.1007/BF00928181
   PALATNIK CB, 1989, INFECT IMMUN, V57, P754, DOI 10.1128/IAI.57.3.754-763.1989
   PALATNIKDESOUSA CB, 1993, ACTA TROP, V53, P59, DOI 10.1016/0001-706X(93)90006-W
   PALATNIKDESOUSA CB, 1994, BRAZ J MED BIOL RES, V27, P547
   PALATNIKDESOUSA.CB, 1994, J BRAZILIAN ASS ADV, V46, P290
   REED SG, 1987, J IMMUNOL, V138, P1596
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   SCHREFFLER WG, 1993, J INFECT DIS, V167, P426
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 25
TC 49
Z9 50
U1 0
U2 4
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 1995
VL 89
IS 4
BP 390
EP 393
DI 10.1016/0035-9203(95)90022-5
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RT595
UT WOS:A1995RT59500019
PM 7570874
DA 2020-12-15
ER

PT J
AU JERONIMO, SMB
   OLIVEIRA, RM
   MACKAY, S
   COSTA, RM
   SWEET, J
   NASCIMENTO, ET
   LUZ, KG
   FERNANDES, MZ
   JERNIGAN, J
   PEARSON, RD
AF JERONIMO, SMB
   OLIVEIRA, RM
   MACKAY, S
   COSTA, RM
   SWEET, J
   NASCIMENTO, ET
   LUZ, KG
   FERNANDES, MZ
   JERNIGAN, J
   PEARSON, RD
TI AN URBAN OUTBREAK OF VISCERAL LEISHMANIASIS IN NATAL, BRAZIL
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID KALA-AZAR; INFECTION
AB The epidemiological pattern of visceral leishmaniasis in north-eastern Brazil is changing. The disease was typically seen in rural, endemic areas, but is now occurring as an epidemic in the city of Natal where 316 cases have been reported since 1989; 49% mere in children less than 5 years of age. The principle clinical and laboratory findings were weight loss, fever, hepato-splenomegaly, anaemia, leucopenia and hypergammaglobulinaemia. Elevated transaminases and hyperbilirubinaemia were also observed. The diagnosis was confirmed in 87% of cases by identifying amastigotes in aspirates from bone marrow or spleen. Five isolates were identified as Leishmania (L.) chagasi by isoenzyme analysis. The mortality rate was 9%; all deaths occurred during the first week in hospital. One person had concurrent human immunodeficiency virus infection. Among 210 household contacts and neighbours of patients from the endemic area examined for evidence of L. (L.) chagasi infection, 6 additional cases of visceral leishmaniasis were diagnosed. Thirty-eight percent of house-mates and neighbours gave a positive Montenegro skin test reaction, indicating prior subclinical infection.
C1 UNIV VIRGINIA, SCH MED, CTR HLTH SCI 485, DEPT MED, DIV GEOG MED, CHARLOTTESVILLE, VA 22903 USA.
   UNIV FED RIO GRANDE NORTE, DEPT BIOCHEM, RIO GRANDE NORTE, BRAZIL.
   FDN NACL SAUDE, NATAL, RN, BRAZIL.
   HOSP GIZELDA TRIGUEIRO, NATAL, RN, BRAZIL.
   UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA.
RI Jeronimo, Selma/AAY-4033-2020; Jeronimo, Selma M.B./M-8672-2014
OI Jeronimo, Selma/0000-0002-4784-9904; Jeronimo, Selma
   M.B./0000-0002-4784-9904
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01-AI-26512] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512, P01AI026512, P01AI026512, P01AI026512, P01AI026512,
   P01AI026512] Funding Source: NIH RePORTER
CR ALENCAR JE, 1962, REV INST MED TROP SP, V3, P175
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   COSTA CHN, 1990, REV SAUDE PUBL, V24, P361, DOI 10.1590/S0034-89101990000500003
   DEANE L. M., 1955, REV BRASIL BIOL, V15, P83
   Deane LM, 1955, HOSPITAL-RIO DE JAN, V48, P61
   EVANS T, 1985, WESTERN J MED, V142, P777
   EVANS TG, 1992, J INFECT DIS, V166, P1124, DOI 10.1093/infdis/166.5.1124
   EVANS TG, 1989, MEM I OSWALDO CRUZ, V84, P157, DOI 10.1590/S0074-02761989000200003
   HALIM MA, 1993, CLIN INFECT DIS, V16, P397, DOI 10.1093/clind/16.3.397
   KHALDI F, 1990, ARCH FR PEDIATR, V47, P257
   MEDRANO FJ, 1992, AIDS, V6, P1499, DOI 10.1097/00002030-199212000-00013
   MONTALBAN C, 1990, J INFECTION, V21, P261, DOI 10.1016/0163-4453(90)93933-J
   PENNA HA, 1934, J BRASILIERO MED, V48, P949
   PETERS BS, 1990, Q J MED, V77, P1101, DOI 10.1093/qjmed/77.2.1101
   VIEIRA JB, 1990, PARASITOL TODAY, V6, P339, DOI 10.1016/0169-4758(90)90180-C
NR 15
TC 96
Z9 105
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 1994
VL 88
IS 4
BP 386
EP 388
DI 10.1016/0035-9203(94)90393-X
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA PE901
UT WOS:A1994PE90100006
PM 7570812
DA 2020-12-15
ER

PT J
AU DIETZE, R
   MILAN, EP
   BERMAN, JD
   GROGL, M
   FALQUETO, A
   FEITOSA, TF
   LUZ, KG
   SUASSUNA, FAB
   MARINHO, LAC
   KSIONSKI, G
AF DIETZE, R
   MILAN, EP
   BERMAN, JD
   GROGL, M
   FALQUETO, A
   FEITOSA, TF
   LUZ, KG
   SUASSUNA, FAB
   MARINHO, LAC
   KSIONSKI, G
TI TREATMENT OF BRAZILIAN KALA-AZAR WITH A SHORT-COURSE OF AMPHOCIL
   (AMPHOTERICIN-B CHOLESTEROL DISPERSION)
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID VISCERAL LEISHMANIASIS; SODIUM STIBOGLUCONATE; STEROL BIOSYNTHESIS;
   KETOCONAZOLE; EFFICACY; TOXICITY; REGIMENS
AB Amphotericin B is an effective but toxic antileishmanial agent. Lipid-encapsulated amphotericin B should have a high therapeutic index for visceral leishmaniasis because reticuloendothelial cells, the sole site in which Leishmania is found, will phagocytize and concentrate the complex. Amphotericin B cholesterol dispersion (Amphocil; 2 mg/[kg.d] intravenously) was administered to 10 Brazilians with kala-azar for 10 days (cohort 1) and to 10 Brazilians with kala-azar for 7 days (cohort 2). All patients were successfully treated: 19 of the 20 patients were without visible parasites in the bone marrow; the mean time to afebrility was 4.2 days; spleen size regressed by a mean of 79% 2 months after therapy; and no patient had clinical or laboratory abnormalities by the end of 6-12 months of follow-up. Side effects were fever and chills accompanied by respiratory distress, but not nephrotoxicity, in children <3 years of age.
C1 FED UNIV ESPIRITO SANTO,TROP MED UNIT,VITORIA,ES,BRAZIL.
   FED UNIV RIO GRANDE NORTE,HOSP GISELDA TRIGUEIRO,DEPT TROP & INFECT DIS,NATAL,RN,BRAZIL.
   LIPOSOME TECHNOL,MENLO PK,CA.
OI Dietze, Reynaldo/0000-0002-6995-8001
CR ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BERENGUER J, 1989, ANN INTERN MED, V111, P129, DOI 10.7326/0003-4819-111-2-129
   BERMAN JD, 1988, REV INFECT DIS, V10, P560
   BERMAN JD, 1986, MOL BIOCHEM PARASIT, V20, P85, DOI 10.1016/0166-6851(86)90145-3
   BERMAN JD, 1992, ANTIMICROB AGENTS CH, V36, P1978, DOI 10.1128/AAC.36.9.1978
   BERMAN JD, 1980, J INFECT DIS, V142, P83, DOI 10.1093/infdis/142.1.83
   CHULAY JD, 1983, J INFECT DIS, V148, P148, DOI 10.1093/infdis/148.1.148
   DAVIDSON RN, 1991, LANCET, V337, P1061, DOI 10.1016/0140-6736(91)91708-3
   FERNANDEZGUERRERO ML, 1987, AM J MED, V83, P1098, DOI 10.1016/0002-9343(87)90948-X
   FIELDING RM, 1992, ANTIMICROB AGENTS CH, V36, P299, DOI 10.1128/AAC.36.2.299
   FRANKE ED, 1990, ANN INTERN MED, V113, P934, DOI 10.7326/0003-4819-113-12-934
   HARDIE WD, 1992, J INFECT DIS, V166, P134, DOI 10.1093/infdis/166.1.134
   HART DT, 1989, MOL BIOCHEM PARASIT, V33, P123, DOI 10.1016/0166-6851(89)90026-1
   HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296
   LEVINE SJ, 1991, ANN INTERN MED, V114, P664, DOI 10.7326/0003-4819-114-8-664
   MISHRA M, 1991, LANCET, V337, P926, DOI 10.1016/0140-6736(91)90268-T
   PRATA ALUIZIO, 1963, TRANS ROY SOC TROP MED AND HYG, V57, P266, DOI 10.1016/0035-9203(63)90183-4
   SAMPAIO S A P, 1971, International Journal of Dermatology, V10, P179, DOI 10.1111/j.1365-4362.1971.tb01694.x
   THAKUR CP, 1988, BRIT MED J, V296, P1557, DOI 10.1136/bmj.296.6636.1557
   1992, MMWR, V41, P131
   1991, AMPHOTERICIN B COLLO
NR 23
TC 57
Z9 59
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC
PY 1993
VL 17
IS 6
BP 981
EP 986
DI 10.1093/clinids/17.6.981
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA ML918
UT WOS:A1993ML91800004
PM 8110956
DA 2020-12-15
ER

EF